

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 September 2008 (12.09.2008)

PCT

(10) International Publication Number
WO 2008/109591 A1

(51) International Patent Classification:

C07D 211/46 (2006.01) **A61K 31/35** (2006.01)
C07D 309/10 (2006.01) **A61K 31/38** (2006.01)
C07D 335/02 (2006.01) **A61K 31/435** (2006.01)
C07D 407/12 (2006.01) **A61P 3/00** (2006.01)

RAWLINS, David Brent [US/US]; 219 Vernon Road,
Morrisville, Pennsylvania 19067 (US).

(74) Agent: **BACHRACH, Max**; Lexicon Pharmaceuticals,
Inc., 8800 Technology Forest Place, The Woodlands, TX
77381 (US).

(21) International Application Number:

PCT/US2008/055775

(22) International Filing Date: 4 March 2008 (04.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/905,714 8 March 2007 (08.03.2007) US
60/948,780 10 July 2007 (10.07.2007) US

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **LEXICON PHARMACEUTICALS, INC.** [US/US]; 8800 Technology Forest Place, The Woodlands, TX 77381 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **GOODWIN, Nicole** [US/US]; 8 Howe Court, Pennington, NJ 18534 (US). **HARRISON, Bryce Alden** [US/US]; 102 Norcross Circle, Hamilton, New Jersey 08619 (US). **KIMBALL, Spencer David** [US/US]; 13 Charred Oak Lane, East Windsor, New Jersey 08520 (US). **MABON, Ross** [GB/US]; 104 Heritage Blvd., Apt. 1, Princeton, New Jersey 08540 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: PHLORIZIN ANALOGS AS INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2

(57) Abstract: Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.

WO 2008/109591 A1

INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE

This application claims priority to U.S. provisional application nos. 60/905,714, filed March 8, 2007, and 60/948,780, filed July 10, 2007, the entireties of which are incorporated
5 herein by reference.

1. FIELD OF THE INVENTION

This invention relates to methods of treating metabolic diseases and disorders such as diabetes, and to compounds and pharmaceutical compositions useful therein.

10 2. BACKGROUND

The sodium glucose co-transporter 2 (SGLT2) is a transporter that reabsorbs glucose from the renal filtrate and prevents the loss of glucose in the urine. Because competitive inhibitors of SGLT2 cause the renal excretion of glucose, they may be used to normalize high blood glucose levels associated with diseases such as diabetes. Handlon, A.L., Expert Opin. Ther. Patents 15(11):1531-1540 (2005).
15


A number of SGLT2 inhibitors have been disclosed. *See, e.g.*, Handlon, *supra*; U.S. patent no. 6,515,117; U.S. patent application publication nos. US 2006/0035841, US 2004/0138439. At least one inhibitor is in clinical development as a treatment for Type 2 diabetes mellitus. *See, e.g.*, Komoroski, B., *et al.*, "Dapagliflozin (BMS-512148), a
20 Selective Inhibitor of the Sodium-Glucose Uptake Transporter 2 (SGLT2), Reduces Fasting Serum Glucose and Glucose Excursion in Type 2 Diabetes Mellitus Patients Over 14 Days" American Diabetes Assn. 67th Scientific Sessions, Abstract 0188-OR (2007).

The first known SGLT2 inhibitor was the natural product phlorizin (glucose, 1-[2-(β -D-glucopyranosyloxy)-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)-1-propanone), and "all
25 subsequent SGLT2 inhibitors have been glycosides derived from its structure." Handlon, *supra*, at 1533. Phlorizin consists of a glucose moiety and two hydroxylated aromatic rings joined by a propanone spacer. Ehrenkranz, J.R.L., *et al.*, Diabetes Metab. Res. Rev. 21:31-38 (2005). A review of the patent literature does not reveal any synthetic SGLT2 inhibitors that do not contain a glucoside moiety or a derivative thereof. Handlon, *supra*. In fact, "because
30 of the relative uniformity of the glycosides in the SGLT2 patent literature, it has become

increasingly difficult for potential drug inventors to find unexplored chemical space.” *Id.* at 1537. But attempts are still being made. *See, e.g.*, U.S. patent application nos. 11/168,905 to Eckhardt *et al.*, entitled “D-Xylopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Such Compounds, Their Use and Process for Their Manufacture;” 11/182,986 to Eckhardt *et al.*, entitled “Methylidene-D-Xylopyranosyl- and Oxo-D-Xylopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Such Compounds, Their Use and Process for Their Manufacture;” and 11/199,962 to Eckhardt *et al.*, entitled “D-Xylopyranosyl-Phenyl-Substituted Cycles, Medicaments Containing Such Compounds, Their Use and Process for Their Manufacture.”

3. SUMMARY OF THE INVENTION


This invention encompasses novel SGLT2 inhibitors. One embodiment of the invention encompasses compounds of the formula:



I

and pharmaceutically acceptable salts and solvates thereof, wherein: A is optionally substituted aryl, cycloalkyl, or heterocycle; X is O, S or NR₃; when X is O, R₁ is OR_{1A}, SR_{1A}, SOR_{1A}, SO₂R_{1A} or N(R_{1A})₂; when X is S, R₁ is hydrogen, OR_{1A}, SR_{1A}, SOR_{1A}, or SO₂R_{1A}; when X is NR₃, R₁ is OR_{1A}, SR_{1A}, SOR_{1A}, SO₂R_{1A}, or R_{1A}; each R_{1A} is independently hydrogen or optionally substituted alkyl, aryl or heterocycle; R₂ is fluoro or OR_{2A}; each of R_{2A}, R_{2B}, and R_{2C} is independently hydrogen, optionally substituted alkyl, C(O)alkyl, C(O)aryl or aryl; R₃ is hydrogen, C(O)R_{3A}, CO₂R_{3A}, CON(R_{3B})₂, or optionally substituted alkyl, aryl or heterocycle; each R_{3A} is independently optionally substituted alkyl or aryl; and each R_{3B} is independently hydrogen or optionally substituted alkyl or aryl.

Another embodiment encompasses compounds of the formula:



II

and pharmaceutically acceptable salt or solvate thereof, wherein: A is optionally substituted
 5 aryl, cycloalkyl, or heterocycle; X is O or NR₃; R₂ is fluoro or OR_{2A}; each of R_{2A}, R_{2B}, and
 R_{2C} is independently hydrogen, optionally substituted alkyl, C(O)alkyl, C(O)aryl or aryl; R₃
 is hydrogen or optionally substituted alkyl, aryl or heterocycle; R₈ is hydrogen or C(O)R_{8A};
 R_{8A} is hydrogen or optionally substituted alkyl, alkoxy or aryl; R_{9A} and R_{9B} are each
 10 independently OR_{9C} or SR_{9C}, or are taken together to provide O, S or NR_{9C}; and each R_{9C} is
 independently optionally substituted alkyl, aryl or heterocycle.


The invention encompasses pharmaceutical compositions comprising the compounds
 disclosed herein. The invention also encompasses methods of inhibiting SGLT2 activity, as
 well as methods of treating, preventing and managing a variety of diseases and disorders.

4. BRIEF DESCRIPTION OF THE FIGURE


15 Certain aspects of this invention can be understood with reference to Figure 1, which
 shows the effect of various compounds of the invention on the urine glucose excretion of
 mice. The compounds were orally dosed at 30 mg/kg.

5. DETAILED DESCRIPTION

This invention is based, in part, on the discovery that compounds of the formulae:



I



II

20 the substituents of which are defined below, can inhibit the sodium glucose co-transporter 2
 (SGLT2).

5.1. Definitions

Unless otherwise indicated, the term “alkenyl” means a straight chain, branched and/or cyclic hydrocarbon having from 2 to 20 (*e.g.*, 2 to 10 or 2 to 6) carbon atoms, and including at least one carbon-carbon double bond. Representative alkenyl moieties include vinyl, allyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 2-decenyl and 3-decenyl.

Unless otherwise indicated, the term “alkoxy” means an –O–alkyl group. Examples of alkoxy groups include, but are not limited to, –OCH₃, –OCH₂CH₃, –O(CH₂)₂CH₃, –O(CH₂)₃CH₃, –O(CH₂)₄CH₃, and –O(CH₂)₅CH₃.

Unless otherwise indicated, the term “alkyl” means a straight chain, branched and/or cyclic (“cycloalkyl”) hydrocarbon having from 1 to 20 (*e.g.*, 1 to 10 or 1 to 4) carbon atoms. Alkyl moieties having from 1 to 4 carbons are referred to as “lower alkyl.” Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, ^oCtyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl and dodecyl. Cycloalkyl moieties may be monocyclic or multicyclic, and examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl. Additional examples of alkyl moieties have linear, branched and/or cyclic portions (*e.g.*, 1-ethyl-4-methyl-cyclohexyl). The term “alkyl” includes saturated hydrocarbons as well as alkenyl and alkynyl moieties.

Unless otherwise indicated, the term “alkylaryl” or “alkyl-aryl” means an alkyl moiety bound to an aryl moiety.

Unless otherwise indicated, the term “alkylheteroaryl” or “alkyl-heteroaryl” means an alkyl moiety bound to a heteroaryl moiety.

Unless otherwise indicated, the term “alkylheterocycle” or “alkyl-heterocycle” means an alkyl moiety bound to a heterocycle moiety.

Unless otherwise indicated, the term “alkynyl” means a straight chain, branched or cyclic hydrocarbon having from 2 to 20 (*e.g.*, 2 to 20 or 2 to 6) carbon atoms, and including at least one carbon-carbon triple bond. Representative alkynyl moieties include acetylenyl, propynyl, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 3-methyl-1-butyne, 4-pentyne, 1-hexynyl, 2-hexynyl, 5-hexynyl, 1-heptyne, 2-heptyne, 6-heptyne, 1-octynyl, 2-octynyl, 7-octynyl, 1-nonyne, 2-nonyne, 8-nonyne, 1-decynyl, 2-decynyl and 9-decynyl.

Unless otherwise indicated, the term “aryl” means an aromatic ring or an aromatic or partially aromatic ring system composed of carbon and hydrogen atoms. An aryl moiety may comprise multiple rings bound or fused together. Examples of aryl moieties include, but are not limited to, anthracenyl, azulenyl, biphenyl, fluorenyl, indan, indenyl, naphthyl, phenanthrenyl, phenyl, 1,2,3,4-tetrahydro-naphthalene, and tolyl.

Unless otherwise indicated, the term “arylalkyl” or “aryl-alkyl” means an aryl moiety bound to an alkyl moiety.

Unless otherwise indicated, the terms “halogen” and “halo” encompass fluorine, chlorine, bromine, and iodine.

Unless otherwise indicated, the term “heteroalkyl” refers to an alkyl moiety (*e.g.*, linear, branched or cyclic) in which at least one of its carbon atoms has been replaced with a heteroatom (*e.g.*, N, O or S).

Unless otherwise indicated, the term “heteroaryl” means an aryl moiety wherein at least one of its carbon atoms has been replaced with a heteroatom (*e.g.*, N, O or S).

Examples include, but are not limited to, acridinyl, benzimidazolyl, benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoquinazolinyl, benzothiazolyl, benzoxazolyl, furyl, imidazolyl, indolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, phthalazinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolinyl, tetrazolyl, thiazolyl, and triazinyl.

Unless otherwise indicated, the term “heteroarylalkyl” or “heteroaryl-alkyl” means a heteroaryl moiety bound to an alkyl moiety.

Unless otherwise indicated, the term “heterocycle” refers to an aromatic, partially aromatic or non-aromatic monocyclic or polycyclic ring or ring system comprised of carbon, hydrogen and at least one heteroatom (*e.g.*, N, O or S). A heterocycle may comprise multiple (*i.e.*, two or more) rings fused or bound together. Heterocycles include heteroaryls.

Examples include, but are not limited to, benzo[1,3]dioxolyl, 2,3-dihydro-benzo[1,4]dioxinyl, cinnolinyl, furanyl, hydantoinyl, morpholinyl, oxetanyl, oxiranyl, piperazinyl, piperidinyl, pyrrolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl and valerolactamyl.

Unless otherwise indicated, the term “heterocyclealkyl” or “heterocycle-alkyl” refers to a heterocycle moiety bound to an alkyl moiety.

Unless otherwise indicated, the term “heterocycloalkyl” refers to a non-aromatic heterocycle.

Unless otherwise indicated, the term “heterocycloalkylalkyl” or “heterocycloalkyl-alkyl” refers to a heterocycloalkyl moiety bound to an alkyl moiety.

Unless otherwise indicated, the term “inhibits SGLT2 *in vivo*” means the inhibition of SGLT2 as determined using the *in vivo* assay described in the Examples, below.

5 Unless otherwise indicated, the terms “manage,” “managing” and “management” encompass preventing the recurrence of the specified disease or disorder in a patient who has already suffered from the disease or disorder, and/or lengthening the time that a patient who has suffered from the disease or disorder remains in remission. The terms encompass
10 modulating the threshold, development and/or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.

Unless otherwise indicated, the term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. Suitable pharmaceutically acceptable base addition salts include, but are not limited to, metallic salts made from aluminum, calcium,
15 lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic,
20 gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonic acid. Specific non-toxic acids include hydrochloric, hydrobromic, phosphoric, sulfuric, and methanesulfonic acids. Examples of specific salts thus include
25 hydrochloride and mesylate salts. Others are well-known in the art. *See, e.g., Remington's Pharmaceutical Sciences*, 18th ed. (Mack Publishing, Easton PA: 1990) and *Remington: The Science and Practice of Pharmacy*, 19th ed. (Mack Publishing, Easton PA: 1995).

Unless otherwise indicated, a “potent SGLT2 inhibitor” is a compound that has a SGLT2 IC₅₀ of less than about 500 nM.

30 Unless otherwise indicated, the terms “prevent,” “preventing” and “prevention” contemplate an action that occurs before a patient begins to suffer from the specified disease or disorder, which inhibits or reduces the severity of the disease or disorder. In other words, the terms encompass prophylaxis.

Unless otherwise indicated, a “prophylactically effective amount” of a compound is an amount sufficient to prevent a disease or condition, or one or more symptoms associated with the disease or condition, or prevent its recurrence. A “prophylactically effective amount” of a compound means an amount of therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.

Unless otherwise indicated, a “selective SGLT2 inhibitor” is a compound that has a SGLT1 IC₅₀ that is at least 10 times greater than its SGLT2 IC₅₀.

Unless otherwise indicated, the term “SGLT1 IC₅₀” is the IC₅₀ of a compound determined using the *in vitro* human SGLT1 inhibition assay described in the Examples, below.

Unless otherwise indicated, the term “SGLT2 IC₅₀” is the IC₅₀ of a compound determined using the *in vitro* human SGLT2 inhibition assay described in the Examples, below.

Unless otherwise indicated, the term “stereoisomeric mixture” encompasses racemic mixtures as well as stereomerically enriched mixtures (*e.g.*, R/S = 30/70, 35/65, 40/60, 45/55, 55/45, 60/40, 65/35 and 70/30).

Unless otherwise indicated, the term “stereomerically pure” means a composition that comprises one stereoisomer of a compound and is substantially free of other stereoisomers of that compound. For example, a stereomerically pure composition of a compound having one stereocenter will be substantially free of the opposite stereoisomer of the compound. A stereomerically pure composition of a compound having two stereocenters will be substantially free of other diastereomers of the compound. A typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound, or greater than about 99% by weight of one stereoisomer of the compound and less than about 1% by weight of the other stereoisomers of the compound.

Unless otherwise indicated, the term “substituted,” when used to describe a chemical structure or moiety, refers to a derivative of that structure or moiety wherein one or more of its hydrogen atoms is substituted with a chemical moiety or functional group such as, but not limited to, alcohol, aldehyde, alkoxy, alkanoyloxy, alkoxy carbonyl, alkenyl, alkyl (*e.g.*, methyl, ethyl, propyl, *t*-butyl), alkynyl, alkyl carbonyloxy (-OC(O)alkyl), amide (-C(O)NH-alkyl- or -alkylNHC(O)alkyl), amidinyl (-C(NH)NH-alkyl- or -C(NR)NH₂), amine (primary, secondary and tertiary such as alkylamino, arylamino, arylalkylamino), aroyl, aryl, aryloxy, azo, carbamoyl (-NHC(O)O-alkyl- or -OC(O)NH-alkyl), carbamyl (*e.g.*, CONH₂, as well as CONH-alkyl, CONH-aryl, and CONH-arylalkyl), carbonyl, carboxyl, carboxylic acid, carboxylic acid anhydride, carboxylic acid chloride, cyano, ester, epoxide, ether (*e.g.*, methoxy, ethoxy), guanidino, halo, haloalkyl (*e.g.*, -CCl₃, -CF₃, -C(CF₃)₃), heteroalkyl, hemiacetal, imine (primary and secondary), isocyanate, isothiocyanate, ketone, nitrile, nitro, oxo, phosphodiester, sulfide, sulfonamido (*e.g.*, SO₂NH₂), sulfone, sulfonyl (including alkylsulfonyl, arylsulfonyl and arylalkylsulfonyl), sulfoxide, thiol (*e.g.*, sulfhydryl, thioether) and urea (-NHCONH-alkyl-).

Unless otherwise indicated, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or condition, or to delay or minimize one or more symptoms associated with the disease or condition. A “therapeutically effective amount” of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of the disease or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.

Unless otherwise indicated, the terms “treat,” “treating” and “treatment” contemplate an action that occurs while a patient is suffering from the specified disease or disorder, which reduces the severity of the disease or disorder, or retards or slows the progression of the disease or disorder.

Unless otherwise indicated, the term “include” has the same meaning as “include, but are not limited to,” and the term “includes” has the same meaning as “includes, but is not limited to.” Similarly, the term “such as” has the same meaning as the term “such as, but not limited to.”


Unless otherwise indicated, one or more adjectives immediately preceding a series of nouns is to be construed as applying to each of the nouns. For example, the phrase “optionally substituted alkyl, aryl, or heteroaryl” has the same meaning as “optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl.”

5 It should be noted that a chemical moiety that forms part of a larger compound may be described herein using a name commonly accorded it when it exists as a single molecule or a name commonly accorded its radical. For example, the terms “pyridine” and “pyridyl” are accorded the same meaning when used to describe a moiety attached to other chemical moieties. Thus, the two phrases “XOH, wherein X is pyridyl” and “XOH, wherein X is
10 pyridine” are accorded the same meaning, and encompass the compounds pyridin-2-ol, pyridin-3-ol and pyridin-4-ol.

It should also be noted that if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or the portion of the structure is to be interpreted as encompassing all stereoisomers of it. Moreover, any
15 atom shown in a drawing with unsatisfied valences is assumed to be attached to enough hydrogen atoms to satisfy the valences. In addition, chemical bonds depicted with one solid line parallel to one dashed line encompass both single and double (*e.g.*, aromatic) bonds, if valences permit.

5.2. Compounds

20 One embodiment of this invention encompasses compounds of the formula:




I

and pharmaceutically acceptable salts and solvates thereof, wherein: A is optionally substituted aryl, cycloalkyl, or heterocycle; X is O, S or NR₃; when X is O, R₁ is OR_{1A}, SR_{1A},
25 SOR_{1A}, SO₂R_{1A} or N(R_{1A})₂; when X is S, R₁ is hydrogen, OR_{1A}, SR_{1A}, SOR_{1A}, or SO₂R_{1A}; when X is NR₃, R₁ is OR_{1A}, SR_{1A}, SOR_{1A}, SO₂R_{1A}, or R_{1A}; each R_{1A} is independently hydrogen or optionally substituted alkyl, aryl or heterocycle; R₂ is fluoro or OR_{2A}; each of R_{2A}, R_{2B}, and R_{2C} is independently hydrogen, optionally substituted alkyl, C(O)alkyl,


C(O)aryl or aryl; R_3 is hydrogen, $C(O)R_{3A}$, CO_2R_{3A} , $CON(R_{3B})_2$, or optionally substituted alkyl, aryl or heterocycle; each R_{3A} is independently optionally substituted alkyl or aryl; and each R_{3B} is independently hydrogen or optionally substituted alkyl or aryl.

Particular compounds are of the formula:


5



Some are of the formula:




Some are of the formula:



10

One embodiment of the invention encompasses compounds of the formula:




15


and pharmaceutically acceptable salts and solvates thereof, wherein: A is optionally substituted aryl, cycloalkyl, or heterocycle; B is optionally substituted aryl, cycloalkyl, or heterocycle; X is O, S or NR_3 ; Y is O, S, SO, SO_2 , NR_4 , $(C(R_5)_2)_p$, $(C(R_5)_2)_q-C(O)-(C(R_5)_2)_q$, $(C(R_5)_2)_q-C(O)O-(C(R_5)_2)_q$, $(C(R_5)_2)_q-OC(O)-(C(R_5)_2)_q$, $(C(R_5)_2)_q-C(O)NR_4-(C(R_5)_2)_q$, $(C(R_5)_2)_q-NR_4C(O)-(C(R_5)_2)_q$, or $(C(R_5)_2)_q-NR_4C(O)NR_4-(C(R_5)_2)_q$; when X is O, R_1 is OR_{1A} , SR_{1A} , SOR_{1A} , SO_2R_{1A} or $N(R_{1A})_2$; when X is S, R_1 is hydrogen, OR_{1A} , SR_{1A} , SOR_{1A} , or SO_2R_{1A} ; when X is NR_3 , R_1 is OR_{1A} , SR_{1A} , SOR_{1A} , SO_2R_{1A} , or R_{1A} ; each R_{1A} is

independently hydrogen or optionally substituted alkyl, aryl or heterocycle; R_2 is fluoro or OR_{2A} ; each of R_{2A} , R_{2B} , and R_{2C} is independently hydrogen, optionally substituted alkyl, $C(O)alkyl$, $C(O)aryl$, or aryl; R_3 is hydrogen, $C(O)R_{3A}$, CO_2R_{3A} , $CON(R_{3B})_2$, or optionally substituted alkyl, aryl or heterocycle; each R_{3A} is independently optionally substituted alkyl or aryl; each R_{3B} is independently hydrogen or optionally substituted alkyl or aryl; each R_4 is independently hydrogen or optionally substituted alkyl; each R_5 is independently hydrogen, hydroxyl, halogen, amino, cyano, OR_{5A} , SR_{5A} , or optionally substituted alkyl; each R_{5A} is independently optionally substituted alkyl; p is 0-3; and each q is independently 0-2.


Particular compounds are of the formula:




Some are of the formula:



Some are of the formula:




Some are of the formula:




wherein: each R_6 is independently hydrogen, hydroxyl, halogen, amino, cyano, nitro, $C\equiv CR_{6A}$, OR_{6A} , SR_{6A} , SOR_{6A} , SO_2R_{6A} , $C(O)R_{6A}$, CO_2R_{6A} , CO_2H , $CON(R_{6A})(R_{6A})$,

- CONH(R_{6A}), CONH₂, NHC(O)R_{6A}, NHSO₂R_{6A}, or optionally substituted alkyl, aryl or heterocycle; each R_{6A} is independently optionally substituted alkyl, aryl or heterocycle; each R₇ is independently hydrogen, hydroxyl, halogen, amino, cyano, nitro, C≡CR_{7A}, OR_{7A}, SR_{7A}, SOR_{7A}, SO₂R_{7A}, C(O)R_{7A}, CO₂R_{7A}, CO₂H, CON(R_{7A})(R_{7A}), CONH(R_{7A}), CONH₂,
 5 NHC(O)R_{7A}, NHSO₂R_{7A}, or optionally substituted alkyl, aryl or heterocycle; each R_{7A} is independently optionally substituted alkyl, aryl or heterocycle; m is 1-3; and n is 1-3.

Some are of the formula:




Some are of the formula:




10

Some are of the formula:



One embodiment of the invention encompasses compounds of the formula:



15

II

and pharmaceutically acceptable salts and solvates thereof, wherein: A is optionally substituted aryl, cycloalkyl, or heterocycle; X is O or NR₃; R₂ is fluoro or OR_{2A}; each of R_{2A}, R_{2B}, and R_{2C} is independently hydrogen, optionally substituted alkyl, C(O)alkyl, C(O)aryl or

aryl; R_3 is hydrogen or optionally substituted alkyl, aryl or heterocycle; R_8 is hydrogen or $C(O)R_{8A}$; R_{8A} is hydrogen or optionally substituted alkyl, alkoxy or aryl; R_{9A} and R_{9B} are each independently OR_{9C} or SR_{9C} , or are taken together to provide O, S or NR_{9C} ; and each R_{9C} is independently optionally substituted alkyl, aryl or heterocycle.

5 With regard to the various formulae disclosed herein, as applicable, particular compounds of the invention are such that A is optionally substituted 6-membered aryl or heterocycle. In others, A is optionally substituted 5-membered heterocycle. In some, A is an optionally substituted fused bicyclic heterocycle.

10 In some, B is optionally substituted 6-membered aryl or heterocycle. In others, B is optionally substituted 5-membered heterocycle. In others, B is an optionally substituted fused bicyclic heterocycle.

In some, X is O. In others, X is S. In others, X is NR_3 .

In some, Y is $(C(R_4)_2)_p$ and, for example, p is 1. In some, Y is $(C(R_5)_2)_q-C(O)-$
 $(C(R_5)_2)_q$ and, for example, each q is independently 0 or 1.

15 In some, R_1 is OR_{1A} . In others, R_1 is SR_{1A} . In others, R_1 is SOR_{1A} . In others, R_1 is SO_2R_{1A} . In others, R_1 is $N(R_{1A})_2$. In others, R_1 is hydrogen. In others, R_1 is R_{1A} .

In some, R_{1A} is hydrogen. In others, R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).

In some, R_2 is fluoro. In others, R_2 is OR_{2A} .

20 In some, R_{2A} is hydrogen.

In some, R_{2B} is hydrogen.

In some, R_{2C} is hydrogen.

In some, R_3 is hydrogen. In others, R_3 is optionally substituted lower alkyl (*e.g.*, optionally substituted methyl).

25 In some, R_4 is hydrogen or optionally substituted lower alkyl.


In some, each R_5 is hydrogen or optionally substituted lower alkyl (*e.g.*, methyl, ethyl, CF_3).

30 In some, R_6 is hydrogen, hydroxyl, halogen, OR_{6A} or optionally substituted lower alkyl (*e.g.*, optionally halogenated methyl, ethyl, or isopropyl). In some, R_6 is hydrogen. In some, R_6 is halogen (*e.g.*, chloro). In some, R_6 is hydroxyl. In some, R_6 is OR_{6A} (*e.g.*, methoxy, ethoxy). In some, R_6 is optionally substituted methyl (*e.g.*, CF_3).

In some, R_7 is hydrogen, $C\equiv CR_{7A}$, OR_{7A} or optionally substituted lower alkyl (*e.g.*, optionally halogenated methyl, ethyl, or isopropyl). In some, R_7 is hydrogen. In some, R_7 is

$C\equiv CR_{7A}$ and R_{7A} is, for example, optionally substituted (*e.g.*, with lower alkyl or halogen) monocyclic aryl or heterocycle. In some, R_7 is OR_{7A} (*e.g.*, methoxy, ethoxy). In some, R_7 is acetylenyl or optionally substituted methyl or ethyl.


Particular compounds of the invention are of the formula:




5

I(a)


Others are of the formula:

**I(b)**

Others are of the formula:


**I(c)**

Others are of the formula:

**I(d)**


15

Others are of the formula:



I(e)

Others are of the formula:



I(f)


In particular compounds of formulae **I(a)-(d)**, X is O. In others, X is S. In others, X is NR₃ and R₃ is, for example, hydrogen. In particular compounds of formulae **I(a)-(f)**, R_{1A} is hydrogen. In others, R_{1A} is optionally substituted methyl or ethyl.

Preferred compounds are potent SGLT2 inhibitors. Particular compounds have a SGLT2 IC₅₀ of less than about 500, 400, 300, 250, 200, 150, 100, 75, 50 or 25 nM.

Particular compounds are selective SGLT2 inhibitors. For example, certain compounds have a SGLT1 IC₅₀ that is at least 10, 15, 20, 25, 50, 75 or 100 times greater than their SGLT2 IC₅₀.

5.3. Methods of Synthesis

Compounds of the invention may be prepared by methods known in the art and by those described herein. For example, compounds may be prepared by methods such as that shown below in Scheme 1:




In this method, known alcohol **1(a)** (*see, e.g., Nucleosides Nucleotides*, 20:649-652 (2001)) is oxidized under suitable conditions (*e.g., with an oxidant such as oxalyl chloride in DMSO*) to form aldehyde **1(b)**. Treatment of a bromide of formula **1(c)** with an agent such as butyl lithium or magnesium bromide followed by addition to aldehyde **1(b)** produces alcohol **1(d)**. Treatment of that compound with an alcohol or water under acidic conditions produces compound **1(e)**. If desired, methods well known in the art may be used to transform compound **1(e)** into various other compounds encompassed by this invention (*e.g., compounds of formula I, wherein one or more of R_{2A} , R_{2B} and R_{2C} is not hydrogen, and/or R_1 is SR_{1A} or NHR_{1A}*).

With regard to scheme 1 and other synthetic approaches described herein, methods of preparing the A and A-Y-B moieties are well known, as are methods of their use to prepare SGLT2 inhibitors. For example, the synthesis of linked diaryl derivatives in the preparation of SGLT2 inhibitors is described in U.S. patent nos. 7,045,665 and 7,053,060; in U.S. patent application nos. 10/735,179; 10/745,075; 11/080,150; and 11/182,986; and in international patent application nos. WO 2006/006496 and WO 2006/089872.

The synthesis of SGLT2 inhibitors containing linked phenyl-carbocycle moieties is described, for example, in U.S. patent application nos. 11/190,315 and 11/199,962.

The synthesis of linked heterocycles and their use to provide SGLT2 inhibitors is described, for example, in U.S. patent application nos. 10/540,519; 10/734,573; 11/247,216; 11/247,356; and in international patent application nos. WO 03/020737; WO 2004/058790; WO 2004/080990; WO 2004/089967; WO 2005/011592; WO 2005/012242; WO 2005/012243; WO 2005/012318; WO 2005/021566; and WO 2005/085265.

Piperidine-based compounds may be prepared by methods such as that shown below in Scheme 2:




5

Scheme 2

In this method, compound **2(a)**, which may be prepared as shown in Scheme 1, is contacted with an azide (*e.g.*, diphenylphosphoryl azide) under conditions sufficient to provide the azide **2(b)**. The azide is then treated under acidic conditions to provide the deprotected furan **2(c)**, which is subsequently treated with a reducing agent (*e.g.*, hydrogen in the presence of platinum oxide) under acidic conditions to provide compound **2(d)**. If desired, methods well known in the art may be used to transform compound **2(d)** into various other compounds encompassed by this invention (*e.g.*, compounds of formula **I**, wherein one or more of R_{2A} , R_{2B} and R_{2C} is not hydrogen, and/or R_1 is SR_{1A} or NHR_{1A}).

15 3:




Scheme 3

In this method, compound **3(a)**, which may be prepared as shown in Scheme 1, is contacted with a suitable sulfur-containing compound (*e.g.*, thioacetate) under suitable

conditions (*e.g.*, in the presence of diethylazodicarboxylate) to form thioacetate **3(b)**. The thioacetate is then treated with a suitable base (*e.g.*, cesium hydroxide) to provide the thiol of formula **3(c)**, which is subsequently treated with an alcohol or water under acidic conditions to provide compound **3(d)**. If desired, methods well known in the art may be used to transform compound **3(d)** into various other compounds encompassed by this invention (*e.g.*, compounds of formula **I**, wherein one or more of R_{2A} , R_{2B} and R_{2C} is not hydrogen, and/or R_1 is SR_{1A} or NHR_{1A}).

Compounds comprising a fluoronated sugar or sugar analogue (compounds of formula **I**, wherein R_2 is F) may be prepared from the correspondingly substituted starting materials using methods known in the art. *See, e.g.*, U.S. patent application no. 10/735,179.

Open-form compounds (*e.g.*, compounds of formula **II**) are readily prepared by methods known in the art. For example, they may be prepared using approaches such as that shown below in Scheme 4:



In this method, compound **4(a)**, which may be prepared as shown in Scheme 1, is contacted with a reactive compound (*e.g.*, methylchloroformate) under suitable conditions to form methyl carbonate **4(b)**. The methyl carbonate is then treated with an alcohol under acidic conditions to provide compound **4(c)**. If desired, methods well known in the art may be used to transform compound **4(c)** into various other compounds encompassed by this invention (*e.g.*, compounds of formula **II**, wherein one or more of R_{2A} , R_{2B} and R_{2C} is not hydrogen).

Using methods known in the art, the synthetic approaches shown above are readily modified to obtain a wide range of compounds. And chiral chromatography and other well-known techniques may be used to obtain stereomerically pure compounds. *See, e.g.*, Jacques, J., *et al.*, Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981);

Wilen, S. H., *et al.*, Tetrahedron 33:2725 (1977); Eliel, E. L., Stereochemistry of Carbon Compounds (McGraw Hill, NY, 1962); and Wilen, S. H., Tables of Resolving Agents and Optical Resolutions, p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972). In addition, syntheses may utilize chiral starting materials to yield stereomerically enriched or pure products.

5.4. Methods of Use

This invention encompasses a method of inhibiting SGLT2 activity, which comprises contacting SGLT2 with an effective amount of a compound of the invention (*i.e.*, a novel compound disclosed herein). In one embodiment, the protein is *in vivo*. In another, it is *ex vivo*.

The invention also encompasses a method of decreasing blood glucose in a patient (*e.g.*, a mammal, such as a human, dog or cat), which comprises administering to the patient an effective amount of a compound of the invention.

The invention also encompasses a method of increasing the excretion of glucose in the urine of a patient, which comprises administering to the patient an effective amount of a compound of the invention.

The invention also encompasses a method of restoring or increasing insulin sensitivity in a patient, which comprises administering to the patient an effective amount of a compound of the invention.

The invention also encompasses a method of treating, managing or preventing a disease or disorder in a patient, which comprises administering to the patient a therapeutically or prophylactically effective amount of a compound of the invention. Examples of diseases and disorders include atherosclerosis, cardiovascular disease, diabetes (Type 1 and 2), hyperglycaemia, hypertension, lipid disorders, obesity, and Syndrome X. A particular disease is type 2 diabetes.

The amount, route of administration and dosing schedule of a compound may depend upon factors such as the specific indication to be treated, prevented or managed, and the age, gender and condition of the patient. The roles played by such factors are well known in the art, and may be accommodated by routine experimentation.

5.5. Pharmaceutical Formulations

This invention encompasses pharmaceutical compositions comprising one or more compounds of the invention. Certain pharmaceutical compositions are single unit dosage forms suitable for oral, mucosal (*e.g.*, nasal, sublingual, vaginal, buccal, or rectal), parenteral (5 (*e.g.*, subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), or transdermal administration to a patient. Examples of dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (*e.g.*, nasal sprays or inhalers); gels; 10 liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (*e.g.*, aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (*e.g.*, crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration 15 to a patient.

The formulation should suit the mode of administration. For example, oral administration requires enteric coatings to protect the compounds of this invention from degradation within the gastrointestinal tract. Similarly, a formulation may contain ingredients that facilitate delivery of the active ingredient(s) to the site of action. For 20 example, compounds may be administered in liposomal formulations, in order to protect them from degradative enzymes, facilitate transport in circulatory system, and effect delivery across cell membranes to intracellular sites.

The composition, shape, and type of a dosage form will vary depending on its use. For example, a dosage form used in the acute treatment of a disease may contain larger 25 amounts of one or more of the active ingredients it comprises than a dosage form used in the chronic treatment of the same disease. Similarly, a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease. These and other ways in which specific dosage forms encompassed by this invention will vary from one another will be readily apparent to those 30 skilled in the art. *See, e.g., Remington's Pharmaceutical Sciences*, 18th ed. (Mack Publishing, Easton PA: 1990).

Pharmaceutical compositions of this invention are preferably administered orally. Discrete dosage forms suitable for oral administration include tablets (*e.g.*, chewable tablets),

caplets, capsules, and liquids (*e.g.*, flavored syrups). Such dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. *See, e.g., Remington's Pharmaceutical Sciences*, 18th ed. (Mack Publishing, Easton PA: 1990).

5 Typical oral dosage forms are prepared by combining the active ingredient(s) in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques. Excipients can take a wide variety of forms depending on the form of preparation desired for administration.


10 Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by conventional methods of pharmacy. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.

15 Disintegrants may be incorporated in solid dosage forms to facility rapid dissolution. Lubricants may also be incorporated to facilitate the manufacture of dosage forms (*e.g.*, tablets).

6. EXAMPLES

Aspects of this invention can be understood from the following examples, which do not limit its scope.

6.1. Example 1: Synthesis of (2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol



The captioned compound was prepared in several steps.

25 A. Preparation of [(3aS,5S,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl]-methanol. This compound was synthesized using procedures known in the art. *See, e.g., Nucleosides Nucleotides*, 20:649-652 (2001) and references therein.

B. Preparation of (3aS,5R,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxole-5-carbaldehyde. To a solution of oxalyl chloride (0.76 ml, 8.7 mmol) in CH₂Cl₂ (55 ml) under N₂ at -78°C was added dropwise a solution of DMSO (0.84 ml, 11.8 mmol) in CH₂Cl₂ (5 ml). After 15 minutes, the alcohol from step A (2.40 g, 7.9 mmol) in CH₂Cl₂ (20 ml) was added dropwise. After 15 minutes, NEt₃ was added slowly. The reaction was allowed to warm slowly to room temperature over 105 minutes, then quenched with H₂O, diluted with Et₂O, and washed with H₂O, sat aq. NaHCO₃, and brine. The combined organic phases were back extracted with Et₂O, which was washed by the same sequence. The combined organic phases were dried of MgSO₄, filtered, and concentrated under vacuum to give (3aS,5R,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxole-5-carbaldehyde (2.4 g, about 64% clean by NMR). The product was carried on without further purification.

C. Preparation of 4-bromo-1-chloro-2-(4-ethoxy-benzyl)-benzene. This compound was prepared as described in U.S. patent application no. 10/745,075 to Deshpande *et al.*, filed December 23, 2003.

D. Preparation of (S)-[(3aS,5S,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl]-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methanol. To a solution of 4-bromo-1-chloro-2-(4-ethoxy-benzyl)-benzene from step C (3.6 g, 11.1 mmol) in THF (60 ml) under N₂ at -78°C was added dropwise BuLi (2.5 M in hexanes, 4.4 ml, 11.1 mmol). After 30 minutes, aldehyde from step B (2.4 g, 64% clean, 5.1 mmol) in THF (20 ml) was added dropwise, and the reaction was stirred for 30 min at -78°C, allowed to warm to room temperature and stirred for 60 minutes, quenched with sat. aq. NH₄Cl, diluted with Et₂O, and washed with H₂O and brine. The combined aqueous washes were back extracted with Et₂O, which was washed by the same sequence. The combined organic extracts were dried over MgSO₄, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (120g SiO₂, 0-20% EtOAc: Hexanes, 75 minutes, 85 ml/min) to give clean (S)-[(3aS,5S,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl]-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methanol (0.84 g, 1.5 mmol, 30%) plus the C5 epimer (0.83g) and some mixed fractions (0.51 g).


¹H NMR (400 MHz, Chloroform-*d*) δ ppm: 7.37 (d, *J*=8.34 Hz, 1 H), 7.18 - 7.23 (m, 1 H), 7.15 (d, *J*=2.02 Hz, 1 H), 7.06 - 7.11 (m, 2 H), 6.80 - 6.84 (m, 2 H), 5.99 (d, *J*=3.79 Hz, 1 H), 5.21 (d, *J*=2.78 Hz, 1 H), 5.11 (d, *J*=2.53 Hz, 1 H), 4.46 (d, *J*=3.54 Hz, 1 H), 3.97 - 4.10

(m, 5 H), 3.95 (t, $J=2.65$ Hz, 1 H), 1.38 - 1.44 (m, 6 H), 1.30 (s, 3 H), 0.84 (s, 9 H), 0.10 (s, 3 H), -0.08 (s, 3 H).

E. Preparation of (2S,3R,4R,5S)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol. A solution of 0.35 M HCl in MeOH was prepared by adding AcCl (0.25 ml, 3.5 mmol) to MeOH (10 ml) and stirring for 15 minutes. The alcohol from step D (0.84g, 1.5 mmol) was treated with this solution for 16 hours at room temperature and 2 hours at 80°C in a sealed vial. The reaction was cooled to room temperature, quenched with K_2CO_3 until basic, diluted with CH_2Cl_2 , filtered, and concentrated under vacuum. The product was purified by flash chromatography (40 g SiO_2 , 0-10% MeOH: CH_2Cl_2 , 60 minutes, 35ml/min), suspended in H_2O , and lyophilized to give (2S,3R,4R,5S)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol (0.46 g, 1.1 mmol, 75%) as a white solid. NMR revealed a 1.2:1 ratio of α and β anomers.

^1H NMR (400 MHz, Chloroform- d) δ ppm: 7.38 - 7.42 (m, 1 H), 7.22 - 7.26 (m, 2 H), 7.11 (d, $J=8.34$ Hz, 2 H), 6.81 - 6.85 (m, 2 H), 4.86 (d, $J=3.79$ Hz, 1 H α), 4.43 (d, $J=9.85$ Hz, 1 H α), 4.34 (d, $J=7.58$ Hz, 1 H β), 4.16 (d, $J=9.35$ Hz, 1 H β), 3.99 - 4.12 (m, 4 H), 3.80 - 3.86 (m, 1 H α), 3.64 - 3.72 (m, 1 H), 3.54 (s, 3 H β), 3.46 - 3.54 (m, 1.5 H), 3.45 (s, 3 H α), 2.69 (d, $J=2.53$ Hz, 1 H β), 2.62 (d, $J=2.27$ Hz, 1 H α), 2.50 (d, $J=2.27$ Hz, 1 H β), 2.12 (d, $J=9.85$ Hz, 1 H α), 2.00 (d, $J=3.03$ Hz, 1 H β), 1.98 (d, $J=2.78$ Hz, 1 H α), 1.41 (t, $J=6.95$ Hz, 3 H). MS (ES+) $[M+NH_4]^+ = 426$.

6.2. Example 2: Synthesis of (3S,4R,5R,6S)-6-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-2,3,4,5-tetraol




The alcohol from Example 1, step D (51 mg, 0.093 mmol) was treated with 1:1 AcOH: H_2O (1 ml) at 80°C in a sealed vial for 18 hours. The reaction was cooled to room temperature, diluted with EtOAc to transfer to a flask, and concentrated under vacuum. The residue was dissolved in CH_2Cl_2 , treated with $NaHCO_3$ and $MgSO_4$ for 30 minutes, filtered, and concentrated under vacuum. The product was purified by flash chromatography (4 g

SiO₂, 0-12% MeOH: CH₂Cl₂, 30 minutes, 10 ml/min), suspended in H₂O, and lyophilized to give (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-2,3,4,5-tetraol (31 mg, 0.079 mmol, 85%) as a white solid. NMR revealed a 1:1 ratio of α and β anomers.

¹H NMR (400 MHz, methanol-*d*₄) δ ppm 7.34 (dd, *J*=8.08, 4.04 Hz, 1 H), 7.22 - 7.30 (m, 2 H), 7.09 (d, *J*=8.34 Hz, 2 H), 6.80 (d, *J*=8.08 Hz, 2 H), 5.16 (d, *J*=3.79 Hz, 1 H α), 4.65 (d, *J*=9.60 Hz, 1 H α or β), 4.59 (d, *J*=7.58 Hz, 1 H α or β), 4.14 (d, *J*=9.60 Hz, 1 H α or β), 3.96 - 4.07 (m, 4 H), 3.76 (t, *J*=9.35 Hz, 1 H α or β), 3.50 (dd, *J*=9.60, 3.79 Hz, 1 H α or β), 3.43 (t, *J*=9.09 Hz, 1 H α or β), 3.23 - 3.29 (m, 1.5 H), 1.36 (t, *J*=7.07 Hz, 3 H). MS (ES+) [M+NH₄]⁺ = 412.


10 **6.3. Example 3: Synthesis of (2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethoxy-tetrahydro-pyran-3,4,5-triol**



A solution of 0.35 M HCl in EtOH was prepared by adding AcCl (0.025 ml, 0.35 mmol) to EtOH (1 ml) and stirring for 15 minutes. The alcohol from Example 1, step D (61 mg, 0.11 mmol) was treated with this solution for 2 hours at 80°C in a sealed vial. The reaction cooled to room temperature, quenched with concentrated NH₄OH until basic, treated with NaHCO₃ for 30 minutes, diluted with CH₂Cl₂, filtered, and concentrated under vacuum. The product was purified by flash chromatography (4 g SiO₂, 0-10% MeOH: CH₂Cl₂, 40 minutes, 10 ml/min), suspended in H₂O, and lyophilized to give (2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethoxy-tetrahydro-pyran-3,4,5-triol (40 mg, 0.095 mmol, 85%) as a white solid. NMR revealed a 1.75:1 ratio of α and β anomers.

¹H NMR (400 MHz, Chloroform-*d*) δ ppm: 7.28 - 7.32 (m, 1 H), 7.14 (m, 2 H), 7.02 (d, *J*=8.84 Hz, 2 H), 6.72 - 6.76 (m, 2 H), 4.88 (d, *J*=4.04 Hz, 1 H α), 4.37 (d, *J*=9.60 Hz, 1 H α), 4.33 (d, *J*=7.83 Hz, 1 H β), 4.06 (d, *J*=9.35 Hz, 1 H β), 3.89 - 4.02 (m, 4 H), 3.36 - 3.87 (m, 5 H), 2.62 (s, 1 H β), 2.54 (s, 1 H α), 2.41 (d, *J*=1.52 Hz, 1 H β), 2.02 (d, *J*=10.36 Hz, 1 H α), 1.92 (d, *J*=2.53 Hz, 1 H), 1.32 (t, *J*=6.95 Hz, 3 H), 1.13 - 1.19 (m, 3 H). MS (ES+) [M+NH₄]⁺ = 440.

6.4. Example 4: Synthesis of (2S,3R,4R,5S,6S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-isopropoxy-tetrahydro-pyran-3,4,5-triol and (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-isopropoxy-tetrahydro-pyran-3,4,5-triol




A solution of 0.35 M HCl in *i*-PrOH was prepared by adding AcCl (0.025 ml, 0.35 mmol) to *i*-PrOH (1 ml) and stirring for 15 minutes. The alcohol from Example 1, step D (68 mg, 0.12 mmol) was treated with this solution for 2 hours at 80°C in a sealed vial. The reaction cooled to room temperature, quenched with concentrated NH₄OH until basic, treated with NaHCO₃ for 30 minutes, diluted with CH₂Cl₂, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (4 g SiO₂, 0-10% MeOH: CH₂Cl₂, 40 minutes, 10 ml/min) to give 50 mg of material, which was further purified by prep HPLC (19x50 mm C18 column, 20-70% MeCN:H₂O (10 mM NH₄OAc), 14 minutes, 30 ml/min) to give (2S,3R,4R,5S,6S)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-isopropoxy-tetrahydro-pyran-3,4,5-triol (β anomer, 7 mg, 0.016 mmol) and (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-isopropoxy-tetrahydro-pyran-3,4,5-triol (α anomer, 25 mg, 0.057 mmol).

(2S,3R,4R,5S,6S)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-isopropoxy-tetrahydro-pyran-3,4,5-triol: ¹H NMR (400 MHz, Chloroform-*d*) δ ppm: 7.37 - 7.40 (m, 1 H), 7.26 (m, 2 H), 7.12 (d, *J*=8.59 Hz, 2 H), 6.80 - 6.84 (m, 2 H), 4.48 (d, *J*=7.83 Hz, 1 H), 4.15 (d, *J*=9.35 Hz, 1 H), 3.95 - 4.10 (m, 5 H), 3.69 (t, *J*=9.09 Hz, 1 H), 3.46 - 3.52 (m, 2 H), 2.69 (br. s., 1 H), 2.43 (br. s., 1 H), 2.05 (br. s., 1 H), 1.41 (t, *J*=7.07 Hz, 3 H), 1.22 (t, *J*=6.57 Hz, 6 H). MS (ES⁺) [M+NH₄]⁺ = 454.

(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-isopropoxy-tetrahydro-pyran-3,4,5-triol: ¹H NMR (400 MHz, Chloroform-*d*) δ ppm 7.39 (d, *J*=8.84 Hz, 1 H), 7.22 (m, 2 H), 7.11 (d, *J*=8.59 Hz, 2 H), 6.80 - 6.85 (m, 2 H), 5.04 (d, *J*=4.04 Hz, 1 H), 4.51 (d, *J*=9.60 Hz, 1 H), 3.98 - 4.10 (m, 4 H), 3.93 (ddd, *J*=12.25, 6.32, 6.19 Hz, 1 H), 3.82 (t, *J*=9.22 Hz, 1 H), 3.62 (dd, *J*=9.47, 3.66 Hz, 1 H), 3.49 (t, *J*=9.22 Hz, 1 H), 2.03 (br s, 3 H), 1.41 (t, *J*=6.95 Hz, 3 H), 1.23 (d, *J*=6.32 Hz, 3 H), 1.19 (d, *J*=6.06 Hz, 3 H). MS (ES⁺) [M+NH₄]⁺ = 454.

6.5. **Example 5: Synthesis of (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol and (2S,3R,4R,5S,6S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol**



A sample of compound from Example 1 step E (80 mg) was dissolved in 4 ml of 30% ethanol/hexanes and injected in 400 μ l portions onto a ChiralPak AD-H column (20x250 mm, 5.5 ml/min, 31.55% ethanol/hexane as eluent isocratic, ambient temperature, 30 min run) to separate the two isomers from each other. The first isomer (r.t. 23 min) was identified as the alpha isomer (6R, 20 mg) and the second (r.t. 26 minutes, 21 mg) was identified as the beta isomer (6S).

(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol: ^1H NMR (400 MHz, Chloroform-*d*) δ ppm 7.39 (d, $J=8.84$ Hz, 1 H), 7.22 - 7.25 (m, 2 H), 7.11 (d, $J=8.59$ Hz, 2 H), 6.83 (d, $J=8.59$ Hz, 2 H), 4.85 (d, $J=4.04$ Hz, 1 H), 4.42 (d, $J=9.60$ Hz, 1 H), 3.99 - 4.11 (m, 4 H), 3.82 (t, $J=9.22$ Hz, 1 H), 3.66 (br. s., 1 H), 3.42 - 3.48 (m, 4 H), 2.79 (br. s., 1 H), 2.23 (d, $J=1.26$ Hz, 1 H), 2.12 (br. s., 1 H), 1.40 (t, $J=6.95$ Hz, 3 H). MS (ES+) $[\text{M}+\text{NH}_4]^+ = 426$.

(2S,3R,4R,5S,6S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol: ^1H NMR (400 MHz, Chloroform-*d*) δ ppm 7.39 (d, $J=8.59$ Hz, 1 H), 7.23 - 7.26 (m, 2 H), 7.11 (d, $J=8.84$ Hz, 2 H), 6.80 - 6.84 (m, 2 H), 4.33 (d, $J=7.58$ Hz, 1 H), 4.07 - 4.17 (m, 2 H), 3.98 - 4.04 (m, 3 H), 3.68 (t, $J=9.09$ Hz, 1 H), 3.46 - 3.55 (m, 5 H), 2.89 (br. s., 1 H), 2.64 (br. s., 1 H), 2.16 (br. s., 1 H), 1.40 (t, $J=7.07$ Hz, 3 H). MS (ES+) $[\text{M}+\text{NH}_4]^+ = 426$.

(2S,3R,4R,5S,6S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol was also synthesized selectively using the following procedure:

A. Preparation of acetic acid (3S,4R,5S,6S)-2,4,5-triacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3-yl ester. The alcohol from Example 1, step D (6.80 g, 12.4 mmol) was treated with 3:2 AcOH/ H_2O (62 ml) at 100°C for 22 hours. The reaction was concentrated under vacuum, rotovapped 3 times with toluene, and placed under high vacuum. The residue was treated with acetic anhydride (9.4 ml, 99.2 mmol) in pyridine (25

ml) for 16 hours. The reaction was quenched with H₂O, stirred 1 hour, diluted with Et₂O, washed with 1 M aq. NaHSO₄, H₂O, sat. aq. NaHCO₃, and brine (with back extraction), dried over MgSO₄, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (120 g SiO₂, 0-50% EtOAc/Hex) to give acetic acid (3S,4R,5S,6S)-2,4,5-triacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3-yl ester (6.10 g, 10.9 mmol, 87%).

¹H NMR (400 MHz, Chloroform-*d*) δ ppm 7.36 (dd, *J*=8.08, 2.02 Hz, 1 H), 7.19 (dt, *J*=8.34, 2.02 Hz, 1 H), 7.07 - 7.09 (m, 1 H), 7.06 (dd, *J*=8.72, 1.64 Hz, 2 H), 6.83 (d, *J*=8.59 Hz, 2 H), 6.44 (d, *J*=3.54 Hz, 0.5 H α), 5.84 (d, *J*=8.08 Hz, 0.5 H β), 5.55 (t, *J*=9.98 Hz, 0.5 H α), 5.33 (t, *J*=9.71 Hz, 0.5 H β), 5.20 - 5.27 (m, 1 H), 5.09 (t, *J*=9.60 Hz, 0.5 H β), 5.03 (t, *J*=9.73 Hz, 0.5 H α), 4.78 (d, *J*=10.11 Hz, 0.5 H α), 4.47 (d, *J*=9.85 Hz, 0.5 H β), 3.94 - 4.09 (m, 4 H), 2.20 (s, 1.5 H α), 2.11 (s, 1.5 H β), 2.06 (s, 1.5 H β), 2.05 (s, 1.5 H α), 2.02 (s, 1.5 H α), 2.01 (s, 1.5 H β), 1.74 (s, 1.5 H α), 1.72 (s, 1.5 H β), 1.41 (t, *J*=6.95 Hz, 3 H). MS (ES+) [M+NH₄]⁺ = 580.

B. Preparation of acetic acid (2S,3S,4R,5S,6S)-4,5-diacetoxy-2-bromo-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3-yl ester. The tetraacetate of step A (8.08 g, 14.4 mmol) was treated with 33% HBr in AcOH (30 ml) for 1 hour. The reaction was diluted with CH₂Cl₂ (60 ml), stirred for 30 minutes, diluted with more DCM, washed 3x with ice cold H₂O and with sat. aq. NaHCO₃ (with back extraction), dried over MgSO₄, filtered, and concentrated under vacuum to give acetic acid (2S,3S,4R,5S,6S)-4,5-diacetoxy-2-bromo-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3-yl ester.

¹H NMR (400 MHz, Chloroform-*d*) δ ppm 7.37 (d, *J*=8.34 Hz, 1 H), 7.17 (dd, *J*=8.21, 2.15 Hz, 1 H), 7.12 (d, *J*=2.27 Hz, 1 H), 7.06 (d, *J*=8.59 Hz, 2 H), 6.83 (d, *J*=8.59 Hz, 2 H), 6.71 (d, *J*=4.04 Hz, 1 H), 5.64 (t, *J*=9.73 Hz, 1 H), 5.10 (t, *J*=9.73 Hz, 1 H), 4.92 - 4.98 (m, 2 H), 3.94 - 4.11 (m, 4 H), 2.13 (s, 3 H), 2.03 (s, 3 H), 1.74 (s, 3 H), 1.41 (t, *J*=7.07 Hz, 3 H). MS (ES+) [M+NH₄]⁺ = 602.

C. Preparation of acetic acid (2S,3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-methoxy-tetrahydro-pyran-3-yl ester. Crude bromide from step B (8.4 g, 14.4 mmol) and ZnO (1.2 g, 14.4 mmol) were dissolved in MeOH (144 ml) and heated at 70 °C for 1 hour. The reaction was cooled to room temperature, filtered through celite with EtOAc, and concentrated under vacuum. The residue was recrystallized from MeOH in two batches to give acetic acid (2S,3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-


benzyl)-phenyl]-2-methoxy-tetrahydro-pyran-3-yl ester (5.98 g, 11.2 mmol, 78%) as the pure β -anomer.

^1H NMR (400 MHz, Chloroform-*d*) δ ppm 7.37 (d, $J=8.08$ Hz, 1 H), 7.22 (dd, $J=8.21$, 2.15 Hz, 1 H), 7.05 - 7.10 (m, 3 H), 6.80 - 6.85 (m, 2 H), 5.29 (t, $J=9.47$ Hz, 1 H), 5.11 (dd, $J=9.73$, 7.96 Hz, 1 H), 5.02 (t, $J=9.73$ Hz, 1 H), 4.54 (d, $J=8.08$ Hz, 1 H), 4.33 (d, $J=9.85$ Hz, 1 H), 3.96 - 4.09 (m, 4 H), 3.49 (s, 3 H), 2.08 (s, 3 H), 1.99 (s, 3 H), 1.71 (s, 3 H), 1.41 (t, $J=6.95$ Hz, 3 H). MS (ES+) $[\text{M}+\text{NH}_4]^+ = 552$.

D. Preparation of (2S,3R,4R,5S,6S)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol. Recrystallized triacetate from step C (5.98 g, 11.2 mmol) was treated with K_2CO_3 (7.7 g, 56 mmol) in MeOH (112 ml) with vigorous stirring for 1 hour. The reaction was filtered through celite and concentrated under vacuum. The residue was dissolved in DCM, washed with H_2O and brine, dried over MgSO_4 , filtered, and concentrated under vacuum. The residue was passed through a plug of silica gel with 5% MeOH: CH_2Cl_2 , concentrated under vacuum, suspended in H_2O , and lyophilized to give (2S,3R,4R,5S,6S)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol (4.37 g, 10.7 mmol, 96%) as a white solid.

^1H NMR (400 MHz, Chloroform-*d*) δ ppm 7.39 (d, $J=8.59$ Hz, 1 H), 7.23 - 7.27 (m, 2 H), 7.11 (d, $J=8.59$ Hz, 2 H), 6.82 (d, $J=8.59$ Hz, 2 H), 4.33 (d, $J=7.83$ Hz, 1 H), 4.15 (d, $J=9.35$ Hz, 1 H), 3.98 - 4.12 (m, 4 H), 3.68 (t, $J=9.09$ Hz, 1 H), 3.53 (s, 3 H), 3.46 - 3.53 (m, 2 H), 2.80 (br. s., 1 H), 2.58 (br. s., 1 H), 2.09 (br. s., 1 H), 1.40 (t, $J=7.07$ Hz, 3 H). MS (ES+) $[\text{M}+\text{NH}_4]^+ = 426$.

6.6. Example 6: Synthesis of N-{(2S,3S,4R,5R,6S)-6-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-yl}-N-propyl-acetamide




The bromide from Example 5, step B (58 mg, 0.1 mmol) was treated with propylamine (0.1 ml) in CH_2Cl_2 (0.5 ml) at 40°C for 1.5 hours. The reaction was blown down with N_2 , then blown down 2 times from CH_2Cl_2 . The residue was treated with acetic anhydride (78 μl , 0.82 mmol) in pyridine (1 ml) overnight. The reaction was quenched with

MeOH, stirred for 30 minutes, diluted with Et₂O, washed with 1 M aq. NaHSO₄, H₂O, sat. aq. NaHCO₃, and brine (with back extraction), dried over MgSO₄, filtered, and concentrated under vacuum. The intermediate was treated with K₂CO₃ (14 mg, 0.10 mmol) in MeOH (1 ml) for 1.5 hours. The reaction was filtered and concentrated under vacuum, and the residue was purified by flash chromatography (12 g SiO₂, 0-10% MeOH:CH₂Cl₂) to give 90% pure material. The product was further purified by HPLC (19x50 mm C18 column, 20-70% MeCN:H₂O (10 mM NH₄OAc), 14 minutes, 30 ml/min), suspended in H₂O, and lyophilized to give N-{(2S,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-yl}-N-propyl-acetamide (3 mg, 0.0063 mmol, 15%) as a 2:1 ratio of rotamers.

¹H NMR (400 MHz, MeOD) δ ppm 7.29 - 7.40 (m, 1 H), 7.16 - 7.26 (m, 2 H), 7.08 (d, *J*=8.6 Hz, 2 H), 6.81 (d, *J*=8.6 Hz, 2 H), 5.59 (d, *J*=8.6 Hz, 0.33 H), 4.98 (d, *J*=11.9 Hz, 0.67 H), 4.25 (d, *J*=9.3 Hz, 0.67 H), 4.17 (d, *J*=9.9 Hz, 0.33 H), 3.92 - 4.06 (m, 4 H), 3.46 - 3.64 (m, 3 H), 3.06 - 3.28 (m, 2 H), 2.16 (s, 3 H), 1.49 - 1.68 (m, 2 H), 1.36 (t, *J*=6.9 Hz, 3 H), 0.93 (t, *J*=7.5 Hz, 1 H), 0.87 (t, *J*=7.5 Hz, 2 H). MS (ES⁺) [M+H]⁺ = 478.


6.7. Example 7: Synthesis of (2R,3S,4S,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-2,3,4,5-tetrahydroxy-pentanal oxime



Compound from Example 2 (50 mg, 0.13 mmol) and hydroxylamine hydrochloride (26 mg, 0.38 mmol) were dissolved in pyridine (0.65 ml) and stirred for 3 hours. The reaction was diluted with EtOAc, washed with 1 M aq. NaHSO₄, H₂O, sat. aq. NaHCO₃, and brine (with back extraction), dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was suspended in H₂O and lyophilized to give (2R,3S,4S,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-2,3,4,5-tetrahydroxy-pentanal oxime (46 mg, 0.11 mmol, 88%) as a 5:1 mixture of oxime isomers.

Major isomer ¹H NMR (400 MHz, MeOD) δ ppm 7.31 - 7.36 (m, 2 H), 7.23 - 7.30 (m, 2 H), 7.10 (d, *J*=8.8 Hz, 2 H), 6.80 (d, *J*=8.6 Hz, 2 H), 4.63 (d, *J*=8.1 Hz, 1 H), 4.28 (t, *J*=6.8 Hz, 1 H), 3.96 - 4.03 (m, 4 H), 3.90 - 3.94 (m, 1 H), 3.59 (dd, *J*=8.0, 1.6 Hz, 1 H), 1.36 (t, *J*=6.9 Hz, 3 H); MS (ES⁺) [M+H]⁺ = 410.

6.8. **Example 8: Synthesis of (3S,4R,5R,6S)-6-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-one oxime**



A. Preparation of acetic acid (3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-hydroxy-tetrahydro-pyran-3-yl ester.

The tetraacetate from Example 5, step A (200 mg, 0.36 mmol) was treated with benzylamine (39 μ l, 0.36 mmol) in DMF (1.8 ml) for 2 hours. The reaction diluted with Et₂O, washed with 1 M aq. NaHSO₄, H₂O, sat. aq. NaHCO₃, and brine, dried over MgSO₄, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (12 g SiO₂, 0-50% EtOAc:Hex.) to give acetic acid (3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-hydroxy-tetrahydro-pyran-3-yl ester (142 mg, 0.27 mmol, 77%) as a 3:1 ratio of anomers.

¹H NMR (400 MHz, Chloroform-*d*) δ ppm 7.33 - 7.40 (m, 1 H), 7.18 - 7.23 (m, 1 H), 7.09 - 7.14 (m, 1 H), 7.06 (d, *J*=8.6 Hz, 2 H), 6.82 (d, *J*=8.6 Hz, 2 H), 5.59 - 5.66 (m, 0.75 H), 5.56 (t, *J*=3.7 Hz, 0.75 H), 5.34 (t, *J*=9.6 Hz, 0.25 H), 4.90 - 5.11 (m, 2.75 H), 4.86 (t, *J*=8.2 Hz, 0.25 H), 4.39 (d, *J*=9.9 Hz, 0.25 H), 3.93 - 4.10 (m, 4 H), 3.36 (d, *J*=8.6 Hz, 0.25 H), 2.81 (dd, *J*=3.8, 1.3 Hz, 0.75 H), 2.12 (s, 0.75 H), 2.12 (s, 2.25 H), 2.02 (s, 0.75 H), 2.01 (s, 2.25 H), 1.73 (s, 2.25 H), 1.72 (s, 0.75 H), 1.41 (t, *J*=7.1 Hz, 3 H); MS (ES⁺) [M+NH₄]⁺ = 538.

B. Preparation of acetic acid (3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-[(Z)-hydroxyimino]-tetrahydro-pyran-3-yl ester.

Compound from step A (142 mg, 0.27 mmol) and hydroxylamine hydrochloride (57 mg, 0.82 mmol) were dissolved in pyridine (1.4 ml). The reaction was stirred for 6 hours, diluted with EtOAc, washed with 1 M aq. NaHSO₄, H₂O, sat. aq. NaHCO₃, and brine (with back extraction), dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was dissolved in CH₂Cl₂, cooled to -78°C, and treated with DBU (49 μ L, 0.33 mmol) followed by N-chlorosuccinimide (44 mg, 0.33 mmol). The reaction was stirred for 20 minutes at -78°C, then allowed to warm to room temperature over 15 minutes. The reaction was diluted with EtOAc, washed with H₂O and brine (with back extraction), dried over MgSO₄, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (12 g SiO₂, 0-50% EtOAc:Hex.) to give


acetic acid (3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-[(Z)-hydroxyimino]-tetrahydro-pyran-3-yl ester (97 mg, 0.18 mmol, 67%).

¹H NMR (400 MHz, Chloroform-*d*) δ ppm 7.42 (d, *J*=8.1 Hz, 1 H), 7.30 (dd, *J*=8.2, 2.1 Hz, 1 H), 7.18 (d, *J*=2.3 Hz, 1 H), 7.07 (d, *J*=8.6 Hz, 2 H), 6.83 (d, *J*=8.6 Hz, 2 H), 6.64 (s, 1 H), 5.53 (d, *J*=4.5 Hz, 1 H), 5.28 (dd, *J*=5.8, 4.5 Hz, 1 H), 5.16 - 5.22 (m, 1 H), 5.10 - 5.15 (m, 1 H), 3.98 - 4.10 (m, 4 H), 2.19 (s, 3 H), 2.07 (s, 3 H), 1.78 (s, 3 H), 1.41 (t, *J*=7.1 Hz, 3 H); MS (ES+) [*M*+H]⁺ = 534.

C. Preparation of (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-one oxime. Compound from step B (97 mg, 0.18 mmol) was treated with 7.0 M NH₃ in MeOH (1.8 ml) for 1 hour. The reaction was concentrated under vacuum, and the residue was purified by flash chromatography (12 g SiO₂, 0-12% MeOH:CH₂Cl₂), suspended in H₂O, and lyophilized to give (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-one oxime (57 mg, 0.14 mmol, 77%) as a white solid.

¹H NMR (400 MHz, MeOD) δ ppm 7.36 - 7.44 (m, 2 H), 7.31 - 7.35 (m, 1 H), 7.12 (d, *J*=8.8 Hz, 2 H), 6.80 (d, *J*=8.8 Hz, 2 H), 4.91 - 4.95 (m, 1 H), 4.14 (d, *J*=5.6 Hz, 1 H), 4.03 - 4.10 (m, 2 H), 3.99 (q, *J*=7.1 Hz, 2 H), 3.73 - 3.78 (m, 1 H), 3.55 (dd, *J*=9.9, 6.6 Hz, 1 H), 1.36 (t, *J*=7.1 Hz, 3 H); MS (ES+) [*M*+H]⁺ = 408.

6.9. Example 9: Synthesis of (2S,3R,4R,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-5-fluoro-6-methoxy-tetrahydro-pyran-3,4-diol



A. Preparation of (2S,3R,4S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate. To a flask charged with 282 mg of tetraacetate from Example 5, step A (0.5 mmol), 1.25 ml of HBr (33% in HOAc) was added. The reaction was stirred for one hour, diluted with 50 ml dichloromethane and quenched by pouring into ice water. The organic layer was separated and washed with saturated aqueous NaHCO₃ and brine. After drying over magnesium sulfate, the solvents were concentration in vacuo. The crude residue was taken up in 0.5 ml dichloromethane and added to a suspension of copper(II) sulfate (20 mg, 0.125 mmol), Zn powder (82 mg, 1.25 mmol), and sodium acetate (984 mg, 12 mmol) in

2.5 ml acetic acid/water (3:2 v:v). This mixture was allowed to stir at room temperature for 4h, after which the reaction was recharged with 20 mg copper(II) sulfate and 82 mg Zn powder and stirred for another 18h. The mixture was quenched with water, extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and removed in vacuo.


- 5 Flash chromatography provided (2S,3R,4S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate (32 mg, 16% yield).

¹H NMR (400 MHz, Chloroform-*d*) δ ppm 7.36 (d, *J*=8.08 Hz, 1 H), 7.20 (dd, *J*=8.08, 2.27 Hz, 1 H), 7.16 (d, *J*=2.27 Hz, 1 H), 7.08 (d, *J*=8.59 Hz, 2 H), 6.82 (d, *J*=8.59 Hz, 2 H), 6.57 (dd, *J*=6.06, 1.52 Hz, 1 H), 5.54 (ddd, *J*=7.07, 2.53, 1.52 Hz, 1 H), 5.32 (dd, *J*=9.60, 7.07 Hz, 1 H), 4.83 - 4.88 (m, 1 H), 4.01 (q, *J*=6.82 Hz, 2 H), 3.96 - 4.10 (m, 2 H), 1.96 (s, 3 H), 1.77 (s, 3 H), 1.40 (t, *J*=6.82 Hz, 3 H). MS (ES+) [M + NH₄]⁺ = 462.

- B. Preparation of (2S,3R,4R,5R,6R)-2-(4-chloro-3-(4-ethoxy-benzyl)-phenyl)-5-fluoro-6-methoxy-tetrahydro-2H-pyran-3,4-diol. SelectfluorTM (45 mg, 0.128 mmol) was added to a solution of compound from step A (38 mg, 0.0853 mmol) in 0.4 mL acetonitrile:methanol (1:1 v:v). The reaction was stirred at ambient temperature and monitored for completion by LCMS. The reaction was quenched with 2 mL saturated aqueous NH₄Cl and extracted with diethyl ether (2 x 5 mL). The organic extracted were dried over sodium sulfate and concentrated in vacuo. Flash chromatography (5 to 10% ethyl acetate/hexanes) provided the fluorinated product. Potassium carbonate (5 mg) was then added to a solution of this isolated product in 0.5 mL of methanol. The reaction was stirred at ambient temperature for 2 h, after which it was quenched with 2 mL water and extracted with ethyl acetate (2 x 4 mL). The organic layer was filtered over a pad of silica and concentrated to provide 6.3 mg of (2S,3R,4R,5R,6R)-2-(4-chloro-3-(4-ethoxy-benzyl)-phenyl)-5-fluoro-6-methoxy-tetrahydro-2H-pyran-3,4-diol as a clear oil.

- 25 ¹H NMR (400 MHz, Chloroform-*d*, 3:2 α:β anomeric ratio, 2:1 axial:equatorial fluorine ratio, isomers due to the minor equatorial fluorine structure is noted in *italics*) δ ppm 7.41 (dd, *J*=8.34, 2.78 Hz, 1 H), 7.20 - 7.33 (m, 2 H), 7.11 (d, *J*=8.59 Hz, 2 H), 6.83 (d, *J*=8.59 Hz, 2 H), 4.92 - 5.02 (m, 1 H), 4.30 - 4.52 (m, 1 H), 3.96 - 4.27 (m, 6 H), 3.74 (t, *J*=9.09 Hz, 0.66 H_α), 3.57/3.56 (s, 3 H), 3.49 (t, *J*=9.09 Hz, 0.33 H_β), 3.42/3.41 (s, 3 H). MS (ES+) [M + NH₄]⁺ = 428.

6.10. Example 10: Synthesis of (2S,3R,4R,5S)-2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol



A. Preparation of [4-(5-bromo-2-chloro-benzyl)-phenoxy]-tert-butyl-dimethyl-silane.

5 This compound was prepared as described in U.S. patent application publication no. 2006/0251728 to Himmelsbach *et al.*, published November 9, 2006.

B. (S)-{3-[4-(tert-butyl-dimethyl-silanyloxy)-benzyl]-4-chloro-phenyl}-

[(3aS,5S,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl]-methanol. A solution of 0.85 g (2.07 mmol) compound from step A in

10 4.14 ml diethyl ether was cooled to -78°C under an inert atmosphere. To this was added 2.66 ml of tert-butyllithium (1.55 M in hexanes, 4.14 mmol) via syringe over 5 minutes. The reaction was stirred at -78°C for 30 minutes. A solution of 0.5 g (1.65 mmol) compound from Example 1, step B in 1.65 ml diethyl ether was added. This reaction mixture was stirred at -78°C for 30 minutes followed by 1.5 h at 0°C. The crude reaction was filtered over a pad
15 of silica gel with excess diethyl ether, which was subsequently removed in vacuo. The product obtained is approximately a 1.2:1 ratio of diastereomers at the newly formed secondary alcohol. The diastereomers were readily separated by chromatography on silica gel (4 to 8% ethyl acetate/hexanes gradient). Yield: 40% (desired diastereomer), 58% (undesired diastereomer).

20 ¹H NMR (400 MHz, Chloroform-*d*) δ ppm 7.17 (d, *J*=8.34 Hz, 1 H), 7.07 - 7.11 (m, 1 H), 7.03 (d, *J*=1.77 Hz, 1 H), 6.85 (d, *J*=8.59 Hz, 2 H), 6.56 (d, *J*=8.34 Hz, 2 H), 5.80 (d, *J*=3.79 Hz, 1 H), 4.70 (d, *J*=4.80 Hz, 1 H), 4.20 (d, *J*=3.79 Hz, 1 H), 4.07 (dd, *J*=4.80, 3.03 Hz, 1 H), 3.97 (d, *J*=3.03 Hz, 1 H), 3.85 (d, *J*=3.03 Hz, 2 H), 3.16 (br. s., 1 H), 1.27 (s, 3 H), 1.13 (s, 3 H), 0.80 (s, 9 H), 0.73 (s, 9 H), 0.00 (s, 6 H), -0.06 (s, 3 H), -0.18 (s, 3 H).


25 C. Preparation of (2S,3R,4R,5S)-2-[4-chloro-3-(4-hydroxy-benzyl)-phenyl]-6-

methoxy-tetrahydro-pyran-3,4,5-triol. Acetyl chloride (0.17 ml) was added to 7 ml of methanol and stirred for 15 minutes at room temperature. This solution was transferred to a vial charged with 0.446 g compound from step B, which was then sealed and heated to 80°C for 1 h. The reaction was cooled to ambient temperature and quenched with 50 ml saturated

aqueous sodium bicarbonate. This aqueous layer was extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine, dried over magnesium sulfate, and the solvent was removed in vacuo. The residue was purified by silica gel chromatography (0 to 20% methanol/dichloromethane gradient) to provide approximately a 1:1 mixture of α : β anomers. Yield: 65%.

^1H NMR (400 MHz, Acetone) δ ppm 8.12 (br. s., 1 H), 7.33 - 7.40 (m, 2 H), 7.29 (dd, $J=8.08$, 1.77 Hz, 1 H), 7.06 (d, $J=8.34$ Hz, 3 H), 6.75 (d, $J=8.34$ Hz, 2 H), 4.73 (d, $J=3.54$ Hz, 0.5 H α), 4.41 (d, $J=9.60$ Hz, 0.5 H α), 4.33 (d, $J=7.58$ Hz, 0.5 H β), 4.19 (d, $J=9.35$ Hz, 0.5 H β), 4.01 (t, $J=3.28$ Hz, 2 H), 3.72 (t, $J=9.09$ Hz, 0.5 H), 3.44 - 3.55 (m, 1 H), 3.41 (s, 1.5 H β), 3.35 (s, 1.5 H α), 3.27 - 3.37 (m, 1.5 H). MS (ES+) $[M + \text{NH}_4]^+ = 398$.

6.11. Example 11: Synthesis of (2S,3R,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3,4,5-triol




Toluene-4-sulfonic acid (S)-(tetrahydro-furan-3-yl) ester (31 mg, 0.126 mmol) was added to a suspension of compound from Example 10, step C (16 mg, 0.042 mmol) and cesium carbonate (46 mg, 0.126 mmol) in 0.22 ml *N,N*-dimethylformamide. The reaction vessel was sealed and heated to 80°C for 15h. Upon cooling to room temperature, the crude reaction mixture was quenched with 2 ml brine and extracted with ethyl acetate (3 x 2 ml). The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Chromatography on silica gel (0 to 10% methanol/dichloromethane gradient) provided (2S,3R,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3,4,5-triol as a clear, viscous oil, which upon concentration in dichloromethane was obtained as a white solid (10 mg, 55% yield).

^1H NMR (400 MHz, Acetone) δ ppm 7.35 - 7.41 (m, 2 H), 7.30 (dd, $J=8.34$, 2.02 Hz, 1 H), 7.16 (d, $J=7.58$ Hz, 2 H), 6.83 (d, $J=8.59$ Hz, 2 H), 4.93 - 5.01 (m, 1 H), 4.74 (d, $J=3.79$ Hz, 0.5 H α), 4.42 (d, $J=9.60$ Hz, 0.5 H α), 4.33 (d, $J=7.58$ Hz, 0.5 H β), 4.20 (d, $J=9.60$ Hz, 0.5 H β), 4.05 (t, $J=2.53$ Hz, 2 H), 4.05 (d, $J=5.31$ Hz, 2 H), 3.93 (dd, $J=10.11$, 4.80 Hz, 1 H), 3.75 - 3.89 (m, 2 H), 3.72 (t, $J=9.09$ Hz, 1 H), 3.50 (t, $J=9.09$ Hz, 1 H), 3.41 (s, 1.5 H β), 3.35

(s, 1.5 H α), 3.29 - 3.34 (m, 3 H), 2.16 - 2.27 (m, 1 H), 1.97 - 2.04 (m, 1 H). MS (ES⁺) [M + NH₄]⁺ = 468.

6.12. Example 12: Synthesis of (2S,3S,4S,5R)-2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-piperidine-3,4,5-triol



5

A. Preparation of ((3aS,5S,6R,6aS)-5-{azido-[(S)-4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methyl}-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yloxy)-tert-butyl-dimethyl-silane. To a solution of the C5 epimer of alcohol from Example 1, step D (682 mg, 1.24 mmol) and PPh₃ (489 mg, 1.87 mmol) in THF (6.2 ml) was added DIAD (366 μ l, 1.87 mmol) followed by diphenyl phosphoryl azide (DPPA, 323 μ l, 1.49 mmol). The reaction was stirred for 1.5 hours, quenched with sat. aq. NH₄Cl, diluted with Et₂O, washed with H₂O and brine (with back extraction), dried over MgSO₄, and concentrated under vacuum. The residue was purified by flash chromatography (40 g SiO₂, 0-8% EtOAc:Hex.) to give ((3aS,5S,6R,6aS)-5-{azido-[(S)-4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methyl}-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yloxy)-tert-butyl-dimethyl-silane (636 mg, 1.11 mmol, 89%) as a yellow oil.

¹H NMR (400 MHz, Chloroform-d) δ ppm 7.40 (d, *J*=8.08 Hz, 1 H), 7.16 - 7.20 (m, 1 H), 7.15 (d, *J*=2.02 Hz, 1 H), 7.10 (d, *J*=8.59 Hz, 2 H), 6.80 - 6.85 (m, 2 H), 5.79 (d, *J*=3.54 Hz, 1 H), 4.58 (d, *J*=9.85 Hz, 1 H), 4.36 (d, *J*=3.54 Hz, 1 H), 4.30 (d, *J*=2.53 Hz, 1 H), 4.14 (dd, *J*=9.98, 2.65 Hz, 1 H), 3.98 - 4.10 (m, 4 H), 1.38 - 1.43 (m, 6 H), 1.29 (s, 3 H), 0.96 (s, 9 H), 0.20 (s, 6 H); MS (ES⁺) [M+NH₄]⁺ = 591.

B. Preparation of (2R,3S,4S,5S)-5-{azido-[(S)-4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methyl}-tetrahydro-furan-2,3,4-triol. Acetyl chloride (0.175 ml, 2.45 mmol) was added to MeOH (7 ml). The solution was stirred 15 minutes, then added to azide from step A (392 mg, 0.68 mmol). The reaction was stirred for 16 hours, then concentrated under vacuum, rotovapped 2 times with MeOH, and placed on the high vacuum to give a white solid. The solid was treated with 1:1 AcOH:H₂O (7 ml) at 100°C for 2.5 hours. The reaction was concentrated under vacuum, rotovapped 2 times with toluene, and placed on the high vacuum. The residue was purified by flash chromatography (40 g SiO₂, 0-6%


MeOH:CH₂Cl₂) to give (2R,3S,4S,5S)-5-{azido-[(S)-4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methyl}-tetrahydro-furan-2,3,4-triol (223 mg, 0.53 mmol, 78%) as a mixture of anomers.

¹H NMR (400 MHz, MeOD) δ ppm 7.39 (dd, *J*=8.46, 3.41 Hz, 1 H), 7.24 - 7.30 (m, 2 H), 7.09 (d, *J*=8.84 Hz, 2 H), 6.81 (dd, *J*=8.59, 1.77 Hz, 2 H), 5.33 (d, *J*=3.54 Hz, 0.5 H),
 5 4.98 (s, 0.5 H), 4.84 (d, *J*=10.17 Hz, 0.5 H), 4.66 (d, *J*=9.09 Hz, 0.5 H), 4.10 - 4.23 (m, 2 H),
 3.97 - 4.05 (m, 4.5 H), 3.89 (dd, *J*=3.66, 1.89 Hz, 0.5 H), 1.36 (t, *J*=6.95 Hz, 3 H); MS (ES⁺)
 [M+NH₄]⁺ = 437.

C. Preparation of (2S,3S,4S,5R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-piperidine-3,4,5-triol. Compound from step B (216 mg, 0.52 mmol) was hydrogenated under
 10 atmospheric pressure H₂ over PtO₂ (6 mg, 0.026 mmol) in MeOH (5 ml) with AcOH (0.25 ml) for 6 hours. The reaction was filtered, concentrated under vacuum, diluted with EtOAc, washed with 10% aq. K₂CO₃ and brine, dried over Na₂SO₄, filtered, and concentrated under vacuum. A portion of the material (about 55 mg) was purified prep HPLC (Sunfire C18
 30x100 mm column, 20-70% MeCN:H₂O (10 mM NH₄OAc), 15 minutes, 45 ml/min) and
 15 lyophilized to give (2S,3S,4S,5R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-piperidine-3,4,5-triol (27 mg, 0.071 mmol) as a white solid.

¹H NMR (400 MHz, MeOD) δ ppm 7.35 (d, *J*=8.08 Hz, 1 H), 7.29 (d, *J*=2.02 Hz, 1 H), 7.21 - 7.25 (m, 1 H), 7.10 (d, *J*=8.34 Hz, 2 H), 6.79 (d, *J*=8.59 Hz, 2 H), 4.02 (s, 2 H),
 3.99 (q, *J*=7.07 Hz, 2 H), 3.57 (ddd, *J*=10.55, 8.65, 5.05 Hz, 1 H), 3.33 - 3.40 (m, 2 H), 3.25 -
 20 3.29 (m, 1 H), 3.12 (dd, *J*=12.00, 5.18 Hz, 1 H), 2.56 (dd, *J*=11.87, 10.86 Hz, 1 H), 1.35 (t, *J*=6.95 Hz, 3 H); MS (ES⁺) [M+H]⁺ = 378.

25 **6.13. Example 13: Synthesis of (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfinyl-tetrahydro-pyran-3,4,5-triol and (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfonyl-tetrahydro-pyran-3,4,5-triol**



A. Preparation of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfonyl-tetrahydro-pyran-3,4,5-triol. To a solution of bromide from Example 5, step B (291 mg, 0.50 mmol) in EtOH (5 ml) at 0°C was added NaSEt (84 mg, 1.0 mmol). The
 30 reaction was stirred 30 minutes, then diluted with EtOAc, washed with dilute aq. NaOH and

with brine (with back extraction), dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (40 g SiO₂, 0-7% MeOH:CH₂Cl₂), suspended in H₂O, and lyophilized to give (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethylsulfanyl-tetrahydro-pyran-3,4,5-triol (126 mg, 0.29 mmol, 58%) as a white powder.


¹H NMR (400 MHz, Chloroform-*d*) δ ppm 7.39 (d, *J*=8.08 Hz, 1 H), 7.18 - 7.26 (m, 2 H), 7.10 (d, *J*=8.59 Hz, 2 H), 6.80 - 6.85 (m, 2 H), 4.46 (d, *J*=9.60 Hz, 1 H), 4.17 (d, *J*=9.35 Hz, 1 H), 3.98 - 4.11 (m, 4 H), 3.67 - 3.73 (m, 1 H), 3.49 - 3.57 (m, 2 H), 2.79 (d, *J*=2.27 Hz, 1 H), 2.67 - 2.77 (m, 2 H), 2.53 (d, *J*=1.77 Hz, 1 H), 2.04 (d, *J*=2.78 Hz, 1 H), 1.41 (t, *J*=6.95 Hz, 3 H), 1.29 (t, *J*=7.45 Hz, 3 H); MS (ES+) [M+NH₄]⁺ = 456.

B. Preparation of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfinyl-tetrahydro-pyran-3,4,5-triol and (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfonyl-tetrahydro-pyran-3,4,5-triol. To a solution of compound from step A (10 mg, 0.023 mmol) in AcOH (0.5 ml) was added H₂O₂ (35 wt% solution in H₂O, 3 mg, 0.092 mmol, 9 μl). The mixture was stirred at ambient temperature for 2 hours before being concentrated under vacuum. Purification of the mixture by silica gel chromatography (5% MeOH/CH₂Cl₂) afforded (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfinyl-tetrahydro-pyran-3,4,5-triol (as a mixture of diastereomers at sulfur) (2 mg, 19%) and (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfonyl-tetrahydro-pyran-3,4,5-triol (5mg, 46%) both as white solids.

(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfinyl-tetrahydro-pyran-3,4,5-triol: ¹H NMR (400 MHz, methanol) δ ppm 7.37 (m, 3 H), 7.31 (m, 1 H), 7.24 (m, 2 H), 7.10 (m, 4 H) 6.81 (m, 4 H), 4.46 (d, *J* = 9.9 Hz, 1 H), 4.28 (d, *J* = 9.6 Hz, 1 H), 4.25 (d, *J* = 9.6 Hz, 1 H), 4.19 (d, *J* = 9.9 Hz, 1 H), 4.03(m, 4 H), 4.00 (m, 4 H), 3.85 (t, *J* = 9.6 Hz, 1 H), 3.76 (t, *J* = 9.6 Hz, 1 H), 3.57(m, 2 H), 3.37 (m, 2 H), 3.09 (m, 1 H), 2.99 (m, 1 H), 2.91 (m, 1 H), 2.80 (m, 1 H), 1.31 (m, 12 H); MS (ES+) [M+H]⁺ = 455.

(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfonyl-tetrahydro-pyran-3,4,5-triol: ¹H NMR (400 MHz, methanol) δ ppm 7.28 (m, 1 H), 7.16 (m, 2 H), 6.99 (d, *J* = 8.6 Hz, 2 H), 6.71 (d, *J* = 8.6 Hz, 2 H), 4.46 (d, *J* = 9.6 Hz, 1 H), 4.19 (d, *J* = 9.4 Hz, 1 H), 3.90 (m, 4 H), 3.81 (t, *J* = 9.3 Hz, 1 H), 3.46 (t, *J* = 9.1 Hz, 1 H), 3.24 (t, *J* = 9.1 Hz, 1 H), 2.98 (m, 2 H), 1.26 (t, *J* = 6.8 Hz, 3 H), 1.18 (t, *J* = 7.6 Hz, 3 H); MS (ES+) [M+NH₄]⁺ = 488.

6.14. Example 14: Synthesis of Acetic acid (2R,3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-methylsulfanyl-tetrahydro-pyran-3-yl ester




5 A. Preparation of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol. To a solution of bromide from Example 5, step B (347 mg, 0.60 mmol.) in EtOH (6 ml) at 0°C was added NaSMe (70 mg, 0.72 mmol.). The reaction was stirred 30 minutes, then diluted with EtOAc, washed with dilute aq. NaOH and with brine (with back extraction), dried over Na₂SO₄, filtered, and concentrated under
10 vacuum. The residue was purified by flash chromatography (40 g SiO₂, 0-7% MeOH:CH₂Cl₂), suspended in H₂O, and lyophilized to give (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol (212 mg, 0.43 mmol., 72%) as a white powder.

¹H NMR (400 MHz, Chloroform-*d*) δ ppm 7.39 (d, *J*=8.34 Hz, 1 H), 7.22 (dd, *J*=8.08, 2.27 Hz, 1 H), 7.17 (d, *J*=2.02 Hz, 1 H), 7.10 (d, *J*=8.59 Hz, 2 H), 6.83 (d, *J*=8.84 Hz, 2 H), 4.38 (d, *J*=9.60 Hz, 1 H), 4.19 (d, *J*=9.35 Hz, 1 H), 3.98 - 4.11 (m, 4 H), 3.67 - 3.73 (m, 1 H), 3.48 - 3.59 (m, 2 H), 2.80 (d, *J*=2.27 Hz, 1 H), 2.53 (d, *J*=2.02 Hz, 1 H), 2.19 (s, 3 H), 2.04 (d, *J*=2.78 Hz, 1 H), 1.41 (t, *J*=6.95 Hz, 3 H); MS (ES⁺) [M+NH₄]⁺ = 442.

B. Preparation of acetic acid (2R,3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-methylsulfanyl-tetrahydro-pyran-3-yl ester. Triol from step A (45 mg, 0.11 mmol.) was treated with acetic anhydride (60 μl, 0.64 mmol.) in pyridine (0.5 ml) for 16 hours. The reaction was diluted with Et₂O, washed with 1 M aq. NaHSO₄, H₂O, sat. aq. NaHCO₃, and brine (with back extraction), dried over MgSO₄, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (4 g SiO₂, 0-25%
20 EtOAc/Hex), suspended in H₂O, and lyophilized to acetic acid (2R,3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-methylsulfanyl-tetrahydro-pyran-3-yl ester (46 mg, 0.087 mmol., 79%) as a white solid.

^1H NMR (400 MHz, Chloroform-*d*) δ ppm 7.36 (d, $J=8.08$ Hz, 1 H), 7.18 (dd, $J=8.21$, 2.15 Hz, 1 H), 7.02 - 7.10 (m, 3 H), 6.83 (d, $J=8.59$ Hz, 2 H), 5.27 - 5.34 (m, 1 H), 5.19 (t, $J=9.60$ Hz, 1 H), 5.04 (t, $J=9.60$ Hz, 1 H), 4.50 (d, $J=9.85$ Hz, 1 H), 4.37 (d, $J=9.85$ Hz, 1 H), 3.95 - 4.08 (m, 4 H), 2.16 (s, 3 H), 2.10 (s, 3 H), 2.00 (s, 3 H), 1.72 (s, 3 H), 1.41 (t, $J=7.07$ Hz, 3 H); MS (ES+) $[\text{M}+\text{NH}_4]^+ = 568$.


6.15. Example 15: Synthesis of (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methanesulfonyl-tetrahydro-pyran-3,4,5-triol



To a solution of the compound from Example 14, step A (41mg, 0.097 mmol) in AcOH (0.5 ml) was added H_2O_2 (35 wt% solution in H_2O , 20 mg, 0.58 mmol, 57 μl). The mixture was stirred at ambient temperature for 18 hours before being concentrated under vacuum. Purification of the mixture by silica gel chromatography (5% MeOH/ CH_2Cl_2) afforded (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methanesulfonyl-tetrahydro-pyran-3,4,5-triol (20mg, 45%) as a white solid.

^1H NMR (400 MHz, methanol) δ ppm 7.28 (m, 1 H), 7.27 (m, 2 H), 7.10 (d, $J = 8.4$ Hz, 2 H), 6.81 (d, $J = 8.4$ Hz, 2 H), 4.53 (d, $J = 9.6$ Hz, 1 H), 4.30 (d, $J = 9.6$ Hz, 1 H), 4.00 (m, 4 H), 3.88 (t, $J = 9.1$ Hz, 1 H), 3.55 (t, $J = 9.1$ Hz, 1 H), 3.35 (t, $J = 9.1$ Hz, 1 H), 2.92 (s, 3 H), 1.36 (t, $J = 6.8$ Hz, 3 H); MS (ES+) $[\text{M} + \text{NH}_4]^+ = 474$.

6.16. Example 16: Synthesis of 1-[(2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidin-1-yl]-ethanone




Preparation of 1-[(2S,3S,4S,5R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidin-1-yl]-ethanone. To a solution of the crude compound from Example 12, step C (38 mg, 0.1 mmol.) in MeOH (1 mL) was added acetic anhydride (19 μL , 0.2 mmol.).

The reaction was stirred for 4 hours, more acetic anhydride (10 μ L, 0.1 mmol) was added, and stirring was continued overnight. The reaction was diluted with EtOAc, washed with sat. aq. NaHCO_3 and brine, dried over Na_2SO_4 , filtered, and concentrated under vacuum. The residue was purified by flash chromatography (12 g SiO_2 , 0-8% $\text{MeOH}:\text{CH}_2\text{Cl}_2$), suspended in H_2O , and lyophilized to give 1-{(2S,3S,4S,5R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidin-1-yl}-ethanone (14 mg, 0.033 mmol., 33% for 2 steps) as a white solid.

^1H NMR (400 MHz, MeOD) δ ppm 7.33 (d, $J=8.34$ Hz, 1 H), 7.18 (dd, $J=8.46$, 2.15 Hz, 1 H), 7.11 (d, $J=1.77$ Hz, 1 H), 7.07 (d, $J=8.84$ Hz, 2 H), 6.81 (d, $J=8.84$ Hz, 2 H), 3.96 - 4.03 (m, 4 H), 3.83 - 3.89 (m, 1 H), 3.73 - 3.77 (m, 1 H), 3.55 - 3.59 (m, 1 H), 2.09 (br. s., 3 H), 1.36 (t, $J=6.95$ Hz, 3 H); MS (ES+) $[\text{M}+\text{H}]^+ = 420$.


6.17. Example 17: Synthesis of (2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester



To a solution of the crude compound from Example 12, step C (38 mg, 0.1 mmol.) and NaHCO_3 (42 mg, 0.5 mmol.) in 1:1:1 EtOAc:EtOH: H_2O (1.5 mL) at 0 $^\circ\text{C}$ was added methyl chloroformate (23 μ L, 0.3 mmol.). The reaction was stirred for 1 hour, then diluted with EtOAc, washed with H_2O and brine (with back extraction), dried over Na_2SO_4 , filtered, and concentrated under vacuum. The residue was purified by flash chromatography (4 g SiO_2 , 0-10% $\text{MeOH}:\text{CH}_2\text{Cl}_2$, suspended in H_2O , and lyophilized to give (2S,3S,4S,5R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester (12 mg, 0.026 mmol., 26% for 2 steps) as a white solid.

^1H NMR (400 MHz, MeOD) δ ppm 7.32 (d, $J=8.34$ Hz, 1 H), 7.15 (dd, $J=8.34$, 2.02 Hz, 1 H), 7.10 (d, $J=2.27$ Hz, 1 H), 7.04 - 7.09 (m, 2 H), 6.81 (d, $J=8.59$ Hz, 2 H), 4.80 (d, $J=6.06$ Hz, 1 H), 4.00 (q, $J=7.07$ Hz, 5 H), 3.81 - 3.86 (m, 1 H), 3.70 - 3.73 (m, 1 H), 3.60 (s, 3 H), 3.54 - 3.59 (m, 1 H), 3.46 (dd, $J=14.40$, 3.28 Hz, 1 H), 1.36 (t, $J=6.95$ Hz, 3 H); MS (ES+) $[\text{M}+\text{H}]^+ = 436$.


6.18. Example 18: Synthesis of (2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid allyl amide



To a solution of the crude compound from Example 12, step C (38 mg, 0.1 mmol.) in 1:1 EtOH:EtOAc (1 mL) was added allyl isocyanate (18 μ L, 0.2 mmol.). The reaction was stirred for 1 hour, then concentrated under vacuum. The residue was purified by flash chromatography (4 g SiO₂, 0-10% MeOH:CH₂Cl₂, suspended in H₂O, and lyophilized to give (2S,3S,4S,5R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid allyl amide (14 mg, 0.030 mmol., 30% for 2 steps) as a white solid.

¹H NMR (400 MHz, MeOD) δ ppm 7.32 (d, J =8.1 Hz, 1 H), 7.16 - 7.20 (m, 2 H), 7.07 (d, J =8.8 Hz, 2 H), 6.80 (d, J =8.8 Hz, 2 H), 5.68 - 5.79 (m, J =17.2, 10.2, 5.3, 5.2 Hz, 1 H), 4.92 - 5.00 (m, 2 H), 4.77 (d, J =6.3 Hz, 1 H), 3.94 - 4.05 (m, 4 H), 3.86 (dd, J =14.0, 3.4 Hz, 1 H), 3.69 - 3.81 (m, 3 H), 3.59 - 3.68 (m, 1 H), 3.56 (dd, J =7.3, 5.1 Hz, 1 H), 3.47 (dd, J =13.9, 3.5 Hz, 1 H), 1.36 (t, J =6.9 Hz, 3 H); MS (ES⁺) [M+H]⁺ = 461.


6.19. Example 19: Synthesis of (2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-methyl-piperidine-3,4,5-triol



To a solution of the compound from Example 12, step C (50 mg, 0.13 mmol.) and K₂CO₃ (55 mg, 0.40 mmol.) in DMF (0.65 mL) was added methyl iodide (10 μ L, 0.16 mmol.). The reaction was stirred for 3 hours, then diluted with EtOAc, washed with H₂O and brine (with back extraction), dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (12 g SiO₂, 2-12% MeOH:CH₂Cl₂), suspended in H₂O, and lyophilized to give (2S,3S,4S,5R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-methyl-piperidine-3,4,5-triol (16 mg, 0.040 mmol., 31%) as a white solid.

¹H NMR (400 MHz, MeOD) δ ppm 7.35 (d, *J*=8.1 Hz, 1 H), 7.20 - 7.24 (m, 1 H), 7.17 (dd, *J*=8.2, 1.9 Hz, 1 H), 7.09 (d, *J*=8.6 Hz, 2 H), 6.80 (d, *J*=8.6 Hz, 2 H), 4.03 (s, 2 H), 3.99 (q, *J*=7.1 Hz, 2 H), 3.64 (ddd, *J*=10.5, 9.2, 4.8 Hz, 1 H), 3.33 - 3.37 (m, 1 H), 3.21 (t, *J*=9.0 Hz, 1 H), 3.03 (dd, *J*=11.1, 4.8 Hz, 1 H), 2.74 (d, *J*=9.3 Hz, 1 H), 2.15 (t, *J*=10.9 Hz, 1 H), 1.95 (s, 3 H), 1.36 (t, *J*=6.9 Hz, 3 H); MS (ES⁺) [*M*+H]⁺ = 392.

6.20. Example 20: Synthesis of (2S,3S,4R,5R,6R)-2-[3-(4-Ethoxy-benzyl)-phenyl]-6-hydroxymethyl-1-methyl-piperidine-3,4,5-triol



A. Preparation of (3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl) tetrahydro-2H-pyran-2-one. Tetra-O-benzyl-D-glucopyranose (2.07 g, 3.8 mmol) was dissolved in DMSO (10.1 mL). To this mixture was added acetic anhydride (7.0 mL) and stirred at room temperature overnight. To the reaction mixture ice was added and stirred for 1 h. The mixture was extracted with ether (3x20 mL). The extract was washed with water (2x10 mL), aqueous sodium bicarbonate (2x10 mL), brine, dried (sodium sulfate) and concentrated under vacuo. Flash silica gel column chromatography with 0-25% ethylacetate/Hexane resulted in 1.712 g of (3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl) tetrahydro-2H-pyran-2-one (83%).

B. Preparation of (3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-2-ol. n-Butyl lithium (2.5N in hexane) (1.263 mL, 3.16 mmol) was added dropwise to a solution of compound from Example 1, step C (1.028 g, 3.16 mmol) in anhydrous THF (15 mL) at -78° C. After stirring for 30 min at -78 °C, a solution of compound from step A (1.7 g, 3.16 mmol) in anhydrous THF (10 mL) was added dropwise and stirred for 1 h while allowing to warm to room temperature. Aqueous ammonium chloride (10 mL) was added to the reaction mixture, THF removed under vacuum, and aqueous layer extracted with ethyl acetate (2x20 mL). Combined organic phases washed with brine, dried (sodium sulfate) and concentrated under vacuum. Crude mixture purified by flash silica gel column chromatography with 0-20% ethyl

acetate/Hexane to give 712 mg of (3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-2-ol (29%). $M+H_2O = 802.1$

C. Preparation of (2R,3R,4S)-2,3,4,6-tetrakis(benzyloxy)-1-(4-chloro-3-(4-ethoxybenzyl)phenyl)hexane-1,5-dione. To a stirred solution of Dess-Martin reagent (500 mg, excess) in CH_2Cl_2 (10 mL) was added compound from step B (500 mg, 0.6 mmol) in anhydrous dichloromethane (10 mL) and stirred overnight. Reaction mixture quenched with 1N sodium hydroxide (3 mL), extracted with dichloromethane (2x10 mL), combined organic fractions were washed with brine, dried over sodium sulfate, concentrated under reduced pressure to get crude product 487 mg. ($M+H_2O = 800.1$)

D. Preparation of (3R,4R,5S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)piperidine. A solution of compound from step C (400 mg, 0.5 mmol), 7N ammonia in MeOH (1.0 mL) and freshly activated 4 Å molecular sieves (250 mg) in dichloromethane (20 mL) were refluxed overnight. The reaction mixture was cooled to room temperature, then sodium cyanoborohydride (160 mg, 2.55 mmol) was added and refluxed for additional 2 h. The reaction mixture was filtered, diluted with dichloromethane (20 mL), washed with water, brine, dried (sodium sulfate), and concentrated under reduced pressure. Chromatography on silica gel (50 to 100% acetonitrile containing 0.1 % ammonium acetate/water gradient) provided (3R,4R,5S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)piperidine (136 mg, 34%).

^1H NMR (400 MHz, Chloroform-*d*) δ ppm 1.41 (t, $J=7.07$ Hz, 3 H) 2.98 (ddd, $J=9.40, 8.50, 2.53$ Hz, 1 H) 3.40 (t, $J=9.22$ Hz, 1 H) 3.41 (t, $J=8.59$ Hz, 1 H) 3.43 (t, $J=9.09$ Hz, 1 H) 3.56 (d, $J=9.35$ Hz, 1 H) 3.68 (t, $J=8.84$ Hz, 1 H) 3.79 (dd, $J=8.97, 2.65$ Hz, 1 H) 3.84 (d, $J=10.36$ Hz, 1 H) 3.97 (d, $J=13.60$ Hz, 1 H) 3.99 (q, $J=7.07$ Hz, 2 H) 4.10 (d, $J=15.30$ Hz, 1 H) 4.43 (d, $J=10.36$ Hz, 1 H) 4.48 (d, $J=2.53$ Hz, 2 H) 4.56 (d, $J=10.86$ Hz, 1 H) 4.88 (d, $J=10.86$ Hz, 1 H) 4.89 (d, $J=11.12$ Hz, 1 H) 4.93 (d, $J=10.86$ Hz, 1 H) 6.77 (d, $J=8.59$ Hz, 2 H) 6.88 (dd, $J=7.71, 1.64$ Hz, 2 H) 7.07 (d, $J=8.59$ Hz, 2 H) 7.16 - 7.38 (m, 21 H); MS (ES+) $[M+H]^+ = 768.2$.

E. Preparation of (3R,4R,5S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-methylpiperidine. Compound from step D (50 mg, 0.065 mmol) was dissolved in acetonitrile (1 mL) and treated with potassium carbonate (18 mg, 0.13 mmol) for 30 minutes. To this mixture iodomethane (20 μ L, 0.32 mmol) was added and stirred overnight. The reaction mixture was diluted with ethyl acetate (10 mL), washed with water, brine, dried (sodium sulfate), and concentrated under vacuum. Chromatography on

silica gel (50 to 100% acetonitrile containing 0.1 % ammonium acetate/water gradient) provided (3R,4R,5S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl) phenyl)-1-methylpiperidine (29 mg, 56 %). MH^+ 782.1.


F. Preparation of (2S,3S,4R,5R,6R)-2-[3-(4-ethoxy-benzyl)-phenyl]-6-

- 5 hydroxymethyl-1-methyl-piperidine-3,4,5-triol. Compound from step E (50 mg) in methanol and acetic acid (25 μ L) was treated 5% wet Pd-C (10 mg) under H_2 atmosphere for 4 h. The reaction mixture was filtered through a pad of celite and concentrated. Chromatography on silica gel (10 to 100% acetonitrile containing 0.1 % ammonium acetate/water gradient) provided (2S,3S,4R,5R,6R)-2-[3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-1-methyl-
- 10 piperidine-3,4,5-triol (6 mg, 70%).

^1H NMR (400 MHz, Chloroform- d) δ ppm 1.40 (t, $J=6.95$ Hz, 3 H) 2.02 (s, 3 H) 2.05 (br. s., 3 H) 2.15 (d, $J=8.84$ Hz, 1 H) 3.01 (d, $J=4.55$ Hz, 2 H) 3.50 (d, $J=5.05$ Hz, 2 H) 3.77 (br. s., 2 H) 3.85 (d, $J=8.59$ Hz, 2 H) 3.91 (br. s., 2 H) 3.99 (q, $J=7.24$ Hz, 2 H) 6.81 (d, $J=8.59$ Hz, 2 H) 7.06 (d, $J=8.59$ Hz, 2 H) 7.09 (br. s., 1 H) 7.18 (br. s., 2 H) 7.24 (d, $J=7.58$

15 Hz, 1 H); MS (ES $^+$) $[M+H]^+ = 387.0$.

6.21. Example 21: Synthesis of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol




- A. Preparation of (S-(1S)-((3aS,6S,6aS)-6-(tert-butyl)dimethylsilyloxy)-2,2-
- 20 dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(4-chloro-3-(4-ethoxybenzyl)phenyl) methyl benzothioate. Diethylazodicarboxylate (150 μ L, 0.914 mmol) was added to a solution of triphenylphosphine (240 mg, 0.914 mmol) in 1.0 mL of THF at room temperature. After one hour, the C5 epimer from Example 1, step D (167 mg, 0.305 mmol) was added in 0.5 mL THF via syringe and was followed by the addition of thiobenzoic acid (110 μ L, 0.914 mmol)
- 25 via syringe. This orange solution was stirred for 22 hours at room temperature. After removal of solvents in vacuo, the residue was purified by flash chromatography (0 to 10% ethyl acetate/hexanes gradient) to provide the title compound as a light yellow oil (104 mg, 50% yield). MS (ES $^+$) $[M + NH_4]^+ = 566$.

B. Preparation of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol. Sodium methoxide (0.3 mL of a 4.3M solution in methanol) was added to a solution of the compound from Step A (104 mg, 0.152 mmol) in 6 mL methanol. After 30 minutes, the reaction was diluted with 20 mL ethyl acetate and washed with water and brine (20 mL each). The organic layer was dried with magnesium sulfate, filtered and solvents removed in vacuo. The residue was purified quickly by flash chromatography (5% ethyl acetate/hexanes) and the product was carried on directly to prevent disulfide formation.

One drop of acetyl chloride was added to 1 mL of methanol and stirred for 15 minutes at room temperature. This acidic solution was added to the free thiol from above and heated for 42 hours at 80 °C. The reaction was cooled to room temperature and the solvent was removed in vacuo. The crude residue was purified by prep HPLC (30 x 250mm C18 column, 5–75% acetonitrile:water (10 mM ammonium acetate), 15 minutes, 45 mL/min) to afford the title compound (alpha anomer, t = 13.82minutes, 8.7 mg, 13% yield for 2 steps).

¹H NMR (400 MHz, acetone-*d*₆) δ ppm 7.33 (m, 2 H), 7.25 (dd, *J*=2.27, 8.34 Hz, 1 H), 7.13 (d, *J*=8.59 Hz, 2 H), 6.82 (d, *J*=8.59 Hz, 2 H), 4.48 (d, *J*=3.03 Hz, 1 H), 4.02 (s, 2 H), 3.99 (q, *J*=7.07 Hz, 2 H), 3.91 (d, *J*=10.36 Hz, 1 H), 3.80-3.85 (m, 2 H), 3.68 (dd, *J*=8.37, 9.35 Hz, 1 H), 3.42 (s, 3 H), 1.33 (t, *J*=7.07 Hz, 3 H). MS (ES⁺) [M + NH₄]⁺ = 424.

6.22. Example 22: Synthesis of (2S,3S,4R,5R,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)-phenyl]-6-hydroxymethyl-piperidine-3,4,5-triol



A. Preparation of (2R,3R,4S,5R,6S)-3,4,5-tris-allyloxy-2-allyloxymethyl-6-methoxy-tetrahydro-pyran. To a solution of α-D-methylglucoside (3 g, 15.45 mmol) in DMF (50 ml) was added NaH (60% dispersion in mineral oil, 3.34 g, 0.14 mol). During this addition, a thick suspension forms and an additional amount of DMF (15 ml) was added to get back into solution. After stirring at room temperature for 30 minutes, the mixture was cooled to 0 °C and allyl bromide (17 g, 0.14 mol, 12 ml) was added slowly. The mixture was then allowed to warm to room temperature and stirred for 18 hours. MeOH was carefully added to the light brown mixture to quench excess NaH and then the mixture was concentrated. The residue

was diluted with CH₂Cl₂ and washed with H₂O, dried (MgSO₄) and concentrated to afford a yellow oil. Purification by silica gel chromatography (20% EtOAc/hexanes) afforded (2R,3R,4S,5R,6S)-3,4,5-tris-allyloxy-2-allyloxymethyl-6-methoxy-tetrahydro-pyran (4.06 g, 11.47 mmol, 74%) as a colorless oil. TLC: R_f = 0.20, 20% EtOAc/hexanes.

- 5 B. Preparation of (3R,4S,5R,6R)-3,4,5-tris-allyloxy-6-allyloxymethyl-tetrahydro-pyran-2-ol. A solution of compound from Step A (10g, 0.028 mol) in AcOH (400 ml) was warmed to 90°C. TfOH (2 N solution in H₂O, 16.69 g, 0.112 mol, 56 ml) was added and the mixture stirred at 90°C for 75 minutes. The solution was cooled and diluted with CH₂Cl₂, washed with H₂O (x3), NaHCO₃ sat., dried (MgSO₄) and concentrated to give a yellow solid.
- 10 Purification by silica gel chromatography (20%-40% EtOAc/hexanes) afforded (3R,4S,5R,6R)-3,4,5-tris-allyloxy-6-allyloxymethyl-tetrahydro-pyran-2-ol as a mixture of anomers (5.85 g, 17.2 mmol, 61%) as a white solid. TLC: R_f = 0.40, 40% EtOAc/hexanes.

- C. Preparation of (3R,4S,5R,6R)-3,4,5-tris-allyloxy-6-allyloxymethyl-tetrahydro-pyran-2-one. Oxalyl chloride (2.75 g, 21.7 mmol, 1.89 ml) was dissolved in CH₂Cl₂ (90 ml)
- 15 and the mixture cooled to -78°C. DMSO (3.39 g, 43.4 mmol, 3.08 ml) was added as a solution in CH₂Cl₂ (60 ml). The mixture was stirred at -78°C for 15 minutes and then compound from Step B (6.70 g, 19.7 mmol) was added as a solution in CH₂Cl₂ (150 ml). The reaction mixture was stirred for a further 15 minutes at -78°C and Et₃N (9.97 g, 98.5 mmol, 13.7 ml) added. The mixture was stirred at -78°C for a further 5 minutes and then allowed to
- 20 warm to room temperature over 30 minutes. The reaction was quenched with H₂O and the organic layer separated, washed twice with H₂O, dried and concentrated to give a pale yellow oil. Purification by silica gel chromatography (15% EtOAc/hexanes) afforded (3R,4S,5R,6R)-3,4,5-tris-allyloxy-6-allyloxymethyl-tetrahydro-pyran-2-one (2.49 g, 7.37 mmol, 37%) as a colorless oil. TLC: R_f = 0.40, 20% EtOAc/hexanes.

- 25 D. Preparation of (3R,4S,5R,6R)-3,4,5-tris-allyloxy-6-allyloxymethyl-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-2-ol. Compound from Example 1, Step C (2.37 g, 7.31 mmol) was dissolved in THF (25 ml) and cooled to -78°C. *n*-BuLi (2.5 N solution in hexanes, 0.47 g, 7.31 mmol, 2.92 ml) was added dropwise and the solution stirred for 15 minutes. Compound from Step C (2.47 g, 7.31 mmol) was added as a solution in THF (25
- 30 ml) and the reaction mixture stirred at -78°C for a further 15 minutes before being allowed to warm to room temperature over 30 minutes. The reaction was quenched with NH₄Cl sat. and the organic layer separated. The aqueous layer was back extracted with Et₂O and the combined organics dried and concentrated to give a yellow oil. Purification by silica gel

chromatography (10%-20% EtOAc/hexanes) afforded (3R,4S,5R,6R)-3,4,5-tris-allyloxy-6-allyloxymethyl-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-2-ol (0.95 g, 1.63 mmol, 22%) as a colorless oil. MS (ES+) $[M+NH_4]^+ = 602$.

E. Preparation of (2R,3R,4S)-2,3,4,6-tetrakis-allyloxy-1-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-hexane-1,5-dione.

To a solution of compound from Step D (0.93 g, 1.59 mmol) in CH_2Cl_2 (25 ml) was added Dess-Martin periodinane (0.68 g, 1.59 mmol). The mixture was stirred at room temperature for 1 hour and then a second portion of Dess-Martin periodinane (1 equiv.) was added. Stirring was continued for another hour and then the reaction was quenched with 1N NaOH (~4 ml). H_2O was added and the organic layer separated. The aqueous layer was back extracted with CH_2Cl_2 , dried and concentrated to give a yellow waxy solid. Purification by silica gel chromatography (15%-20% EtOAc/hexanes) afforded (2R,3R,4S)-2,3,4,6-tetrakis-allyloxy-1-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-hexane-1,5-dione (0.60 g, 1.03 mmol, 65%) as a white solid. MS (ES+) $[M+NH_4]^+ = 600$.

F. Preparation of (2R,3R,4R,5S,6S)-3,4,5-tris-allyloxy-2-allyloxymethyl-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-piperidine.

To a solution of compound from Step E (0.60 g, 1.03 mmol) in MeOH (12 ml) was added 4 Å MS followed by ammonium formate (0.13 g, 2.06 mmol). $NaBH_3CN$ (0.14 g, 2.3 mmol) was then added in one portion and the mixture stirred at room temperature for 1 hour 30 minutes. The reaction mixture was then filtered and concentrated. Purification by silica gel chromatography (10%-20% EtOAc/hexanes) afforded (2R,3R,4R,5S,6S)-3,4,5-tris-allyloxy-2-allyloxymethyl-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-piperidine (155 mg, 0.27 mmol, 27%). MS (ES+) $[M+H]^+ = 568$.

G. Preparation of (2S,3S,4R,5R,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-tris-[(E)-propenyl]oxy]-6-[(E)-propenyl]oxymethyl]-piperidine.

$Ir(COD)[P(CH_3Ph)_2]PF_6$ (8 mg, 30 mol%) in THF (0.3 ml) was stirred under an atmosphere of H_2 until the color changed from red to pale yellow (~5 minutes). Compound from Step F (19 mg, 0.033 mol) in THF (0.5 ml) was then added and the mixture stirred at room temperature for 45 minutes and then concentrated. Purification by silica gel chromatography (20% EtOAc/hexanes) afforded (2S,3S,4R,5R,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-tris-[(E)-propenyl]oxy]-6-[(E)-propenyl]oxymethyl]-piperidine (15 mg, 0.026 mmol, 80%) as a colorless oil. MS (ES+) $[M+H]^+ = 568$.


H. Preparation of (2S,3S,4R,5R,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-piperidine-3,4,5-triol.

Compound from Step G (15 mg, 0.026 mmol) was dissolved in a solution of THF/AcOH/1NHCl (0.2 ml:0.3 ml:0.15 ml) and heated to 70°C for

30 minutes. The mixture was concentrated to give a pale yellow oil. Purification by preparative HPLC (sunfire C18, 30x100 mm, 5 μ m, 10%-100% B over 15 minutes) afforded (2S,3S,4R,5R,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-piperidine-3,4,5-triol (5 mg, 0.012 mmol, 46%) as a white solid. MS (ES+) $[M+H]^+ = 408$.

¹H NMR (400 MHz, MeOD) δ ppm 7.36 (m, 2H), 7.28 (m, 1H), 7.12 (d, $J = 8.6$ Hz, 2H), 6.81 (d, $J = 8.6$ Hz, 2H), 4.05 (m, 2H), 4.00 (q, $J = 6.8$ Hz, 2H), 3.92 (dd, $J = 3.0$ Hz and 10.8Hz, 1H), 3.58 (dd, $J = 7.6$ Hz and 11.1Hz, 1H), 3.47 (m, 1H), 3.26-3.36 (m, 3H), 2.70 (m, 1H), 1.37 (t, $J = 7.1$ Hz, 3H).

6.23. Example 23: Synthesis of (2S,3S,4R,5R,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-1-methyl-piperidine-3,4,5-triol



A. Preparation of (2R,3R,4R,5S,6S)-3,4,5-tris-allyloxy-2-allyloxymethyl-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-methyl-piperidine. To a solution of compound from Example 22, Step F (135 mg, 0.24 mmol) in MeCN was added K_2CO_3 (164 mg, 1.19 mmol). The mixture was stirred for 30 minutes and then MeI (676 mg, 4.76 mmol) was added. Stirring was continued at room temperature for 8 hours, then the mixture was filtered and concentrated. Purification by silica gel chromatography (10% EtOAc/hexanes) afforded (2R,3R,4R,5S,6S)-3,4,5-tris-allyloxy-2-allyloxymethyl-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-methyl-piperidine (90mg, 0.15mmol, 65%) as a colorless oil. MS (ES+) $[M+H]^+ = 582$.

B. Preparation of (2S,3S,4R,5R,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-methyl-3,4,5-tris-[(E)-propenyl]oxy-6-[(E)-propenyl]oxymethyl-piperidine.

$Ir(COD)[PCH_3Ph_2]PF_6$ (27 mg, 30 mol%) in THF (1 ml) was stirred under an atmosphere of H_2 until the color changed from red to pale yellow (~5 minutes). Compound from Step A (62 mg, 0.11 mol) in THF (1.5 ml) was then added and the mixture stirred at room temperature for 45 minutes and then concentrated. Purification by silica gel chromatography (20% EtOAc/hexanes) afforded (2S,3S,4R,5R,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-methyl-3,4,5-tris-[(E)-propenyl]oxy-6-[(E)-propenyl]oxymethyl-piperidine (62 mg, 0.11 mmol, 100%) as a colorless oil. MS (ES+) $[M+H]^+ = 582$.

C. Preparation of (2S,3S,4R,5R,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-1-methyl-piperidine-3,4,5-triol. Compound from Step B (54 mg, 0.093 mmol) was dissolved in a solution of THF/AcOH/1NHCl (0.5 ml:0.6 ml:0.30 ml) and heated to 70°C for 30 minutes. The mixture was concentrated to give a pale yellow oil. Purification by preparative HPLC (sunfire C18, 30x100 mm, 5 µm, 10%-100% B over 15 minutes) afforded (2S,3S,4R,5R,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-1-methyl-piperidine-3,4,5-triol (22 mg, 0.052 mmol, 56%) as a white solid. MS (ES+) [M+H]⁺ = 422.

¹H NMR (400 MHz, MeOD) δ ppm 7.31 (m, 2H), 7.22 (m, 1H), 7.07 (d, *J* = 8.8Hz, 2H), 6.77 (d, *J* = 8.8Hz, 2H), 4.00 (m, 2H), 3.96 (q, *J* = 7.1Hz, 2H), 3.90 (m, 2H), 3.52 (dd, *J* = 9.4Hz and 9.4Hz, 1H), 3.23-3.32 (m, 3H), 2.88(d, *J* = 8.8Hz, 1H), 2.00 (s, 3H), 1.34 (t, *J* = 7.1Hz, 3H).

6.24. Additional Compounds

Using the procedures described herein and methods known in the art, the additional compounds listed below in Table 1 were prepared. Potent SGLT2 inhibitors are marked with an asterisk.

Table 1

Compound	Molecular Formula	MS (M+H) ⁺
(2S,3R,4R,5S)-2-[3-(4-Ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₁ H ₂₆ O ₆	374
(2S,3R,4R,5S,6S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(2-hydroxy-ethoxy)-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₇ ClO ₇	438.1
(3S,4R,5R,6S)-2-Benzyl-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3,4,5-triol*	C ₂₇ H ₂₉ ClO ₆	484.1
(2S,3R,4R,5S)-2-(4'-Ethoxy-biphenyl-3-yl)-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₀ H ₂₄ O ₆	378 (M+NH ₃) ⁺
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(2,2,2-trifluoro-ethoxy)-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₄ ClF ₃ O ₆	476.1
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(2-methoxy-ethoxy)-tetrahydro-pyran-3,4,5-triol*	C ₂₃ H ₂₉ ClO ₇	452.1

(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(2-dimethylamino-ethoxy)-tetrahydro-pyran-3,4,5-triol*	C ₂₄ H ₃₂ ClNO ₆	466.1
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-propylsulfanyl-tetrahydro-pyran-3,4,5-triol*	C ₂₃ H ₂₉ ClO ₅ S	452
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-imidazol-1-yl-tetrahydro-pyran-3,4,5-triol	C ₂₃ H ₂₅ ClN ₂ O ₅	445.1
{(3S,4R,5R,6S)-6-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-yloxy}-acetic acid methyl ester*	C ₂₃ H ₂₇ ClO ₈	466.1
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(4-methyl-piperidin-1-yl)-tetrahydro-pyran-3,4,5-triol	C ₂₆ H ₃₄ ClNO ₅	475.1
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(5-methyl-thiazol-2-ylamino)-tetrahydro-pyran-3,4,5-triol	C ₂₄ H ₂₇ ClN ₂ O ₅ S	491
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-phenoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₆ H ₂₇ ClO ₆	470.1
N- {(2S,3S,4R,5R,6S)-6-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-yl}-N-methyl-acetamide	C ₂₃ H ₂₈ ClNO ₆	450
Acetic acid (2S,3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-methoxy-tetrahydro-pyran-3-yl ester	C ₂₇ H ₃₁ ClO ₉	552 (M+NH ₃) ⁺
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-phenoxy)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol	C ₂₀ H ₂₃ ClO ₇	428 (M+NH ₃) ⁺
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-methoxy-phenylsulfanyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₁₉ H ₂₁ ClO ₆ S	430 (M+NH ₃) ⁺
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-methoxy-benzenesulfinyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol	C ₁₉ H ₂₁ ClO ₇ S	429
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(3-hydroxy-propoxy)-tetrahydro-pyran-3,4,5-triol*	C ₂₃ H ₂₉ ClO ₇	452.2
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(2-hydroxy-ethylsulfanyl)-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₇ ClO ₆ S	472 (M+NH ₃) ⁺

(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(2-mercapto-ethoxy)-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₇ ClO ₆ S	456.3
(2S,3R,4R,5S)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(2,3-dihydroxy-propoxy)-tetrahydro-pyran-3,4,5-triol*	C ₂₃ H ₂₉ ClO ₈	468.2
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-(2-methoxy-ethoxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₇ ClO ₇	456 (M+NH ₃) ⁺
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethylsulfanyl-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₇ ClO ₅ S	456 (M+NH ₃) ⁺
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol*	C ₂₁ H ₂₅ ClO ₅ S	442 (M+NH ₃) ⁺
[2-Chloro-5-((2S,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methoxy-tetrahydro-pyran-2-yl)-phenyl]-(4-ethoxy-phenyl)-methanone*	C ₂₁ H ₂₃ ClO ₇	423
(2S,3R,4R,5S,6S)-2-{4-Chloro-3-[(4-ethoxy-phenyl)-hydroxy-methyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₁ H ₂₅ ClO ₇	407
(2S,3R,4R,5S)-2-[3-(4-Ethoxy-benzyl)-4-methyl-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₈ O ₆	406 (M+NH ₃) ⁺
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-(2-methylsulfanyl-ethoxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₇ ClO ₆ S	472 (M+NH ₃) ⁺
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-(pyridin-4-yloxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₄ H ₂₄ ClNO ₆	458
(2S,3R,4R,5S,6S)-2-(4-Chloro-3-{(4-ethoxy-phenyl)-[(Z)-propylimino]-methyl}-phenyl)-6-methoxy-tetrahydro-pyran-3,4,5-triol	C ₂₄ H ₃₀ ClNO ₆	464
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-(thiazol-2-yloxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₂ ClNO ₆ S	464
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-(pyrimidin-5-yloxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₃ H ₂₃ ClN ₂ O ₆	459
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-(2,6-dimethoxy-pyrimidin-4-yloxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₅ H ₂₇ ClN ₂ O ₈	519

2-{(2R,3S,4R,5R,6S)-6-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylsulfanyl}-acetamide*	C ₂₂ H ₂₆ ClNO ₆ S	468.1
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(furan-2-ylmethylsulfanyl)-tetrahydro-pyran-3,4,5-triol*	C ₂₅ H ₂₇ ClO ₆ S	490.1
(2S,3R,4R,5S,6S)-2-{4-Chloro-3-[(4-ethoxy-phenyl)-imino-methyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol	C ₂₁ H ₂₄ ClNO ₆	422
(2S,3R,4R,5S,6S)-2-{3-[(4-Ethoxy-phenyl)-hydroxy-methyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol	C ₂₁ H ₂₆ O ₇	390
(2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid benzyl ester	C ₂₈ H ₃₀ ClNO ₆	511
(2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid allylamide*	C ₂₄ H ₂₉ ClN ₂ O ₅	461
N-(2-{(2R,3S,4R,5R,6S)-6-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylsulfanyl}-ethyl)-acetamide*	C ₂₄ H ₃₀ ClNO ₆ S	496.1
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(2,2,2-trifluoro-ethylsulfanyl)-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₄ ClF ₃ O ₅ S	492.1
(2S,3R,4R,5S,6S)-2-{4-Chloro-3-[1-(4-ethoxy-phenyl)-1-hydroxy-ethyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol	C ₂₂ H ₂₇ ClO ₇	438
Dimethyl-thiocarbamic acid O-{4-[2-chloro-5-((2S,3R,4R,5S)-3,4,5-trihydroxy-6-methoxy-tetrahydro-pyran-2-yl)-benzyl]-phenyl} ester*	C ₂₂ H ₂₆ ClNO ₆ S	468
(2S,3R,4R,5S,6S)-2-{3-[1-(4-Ethoxy-phenyl)-ethyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol	C ₂₂ H ₂₈ O ₆	406 (M+NH ₃) ⁺
Diethyl-dithiocarbamic acid (2R,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-yl ester	C ₂₅ H ₃₂ ClNO ₅ S ₂	526.2
(2S,3R,4R,5S,6S)-2-(4-Chloro-3-{4-[(R)-(tetrahydro-furan-3-yl)oxy]-benzyl}-phenyl)-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₃ H ₂₇ ClO ₇	468 (M+NH ₃) ⁺

(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethanesulfinyl-tetrahydro-pyran-3,4,5-triol*	C ₂₂ H ₂₇ ClO ₆ S	455
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-((S)-1-methyl-pyrrolidin-3-yloxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₄ H ₃₀ ClNO ₆	522 (M-H+Ac)
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-(tetrahydro-pyran-4-yloxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₄ H ₂₉ ClO ₇	523 (M-H+Ac)
(2S,3R,4R,5S)-2-(4-Chloro-3-{4-hydroxy-3-[1-(2-methylamino-ethyl)-allyl]-benzyl}-phenyl)-6-methoxy-tetrahydro-pyran-3,4,5-triol	C ₂₅ H ₃₂ ClNO ₆	478
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-(1-methyl-piperidin-4-yloxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₅ H ₃₂ ClNO ₆	478
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methanesulfinyl-tetrahydro-pyran-3,4,5-triol*	C ₂₁ H ₂₅ ClO ₆ S	441
(2S,3S,4S,5R)-1-Benzyl-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-piperidine-3,4,5-triol*	C ₂₇ H ₃₀ ClNO ₄	468
(2S,3R,4R,5S)-2-{3-[4-(2-Benzylloxy-ethoxy)-benzyl]-4-chloro-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₈ H ₃₁ ClO ₇	532 (M+NH ₃) ⁺
(2S,3R,4R,5S)-2-{3-[4-(2-Hydroxy-ethoxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₁ H ₂₆ O ₇	408 (M+NH ₃) ⁺
(2S,3R,4R,5S)-2-{4-Chloro-3-[4-(2-hydroxy-ethoxy)-benzyl]-phenyl}-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₁ H ₂₅ ClO ₇	442 (M+NH ₃) ⁺
2-{(2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidin-1-yl}-acetamide*	C ₂₂ H ₂₇ ClN ₂ O ₅	435
(2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-isobutyl-piperidine-3,4,5-triol*	C ₂₄ H ₃₂ ClNO ₄	492 (M-H+Ac)
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(2-methyl-tetrahydro-furan-3-ylsulfanyl)-tetrahydro-pyran-3,4,5-triol*	C ₂₅ H ₃₁ ClO ₆ S	512 (M+NH ₃) ⁺
(R)-2-Amino-3-{(2R,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylsulfanyl}-propionic acid*	C ₂₃ H ₂₈ ClNO ₇ S	498

(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-cyclopentylsulfanyl-tetrahydro-pyran-3,4,5-triol*	C ₂₅ H ₃₁ ClO ₅ S	496 (M+NH ₃) ⁺
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-cyclohexylsulfanyl-tetrahydro-pyran-3,4,5-triol	C ₂₆ H ₃₃ ClO ₅ S	510 (M+NH ₃) ⁺
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(3-methyl-butylsulfanyl)-tetrahydro-pyran-3,4,5-triol*	C ₂₅ H ₃₃ ClO ₅ S	498 (M+NH ₃) ⁺
(2S,3R,4R,5S)-2-[3-(4-Ethoxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol*	C ₂₇ H ₃₁ ClO ₉	552 (M+NH ₃) ⁺
1-{(2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidin-1-yl}-ethanone*	C ₂₂ H ₂₆ ClNO ₅	420
(2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid benzyl ester	C ₂₈ H ₃₀ ClNO ₆	529 [M+NH ₄] ⁺
(2S,3S,4S,5R)-1-Benzyl-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-piperidine-3,4,5-triol*	C ₂₇ H ₃₀ ClNO ₄	468
2-{(2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidin-1-yl}-acetamide*	C ₂₂ H ₂₇ ClN ₂ O ₅	435
(2S,3S,4S,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-isobutyl-piperidine-3,4,5-triol*	C ₂₄ H ₃₂ ClNO ₄	492 [M+Ac] ⁻
(3S,4R,5R)-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-piperidine-3,4,5-triol*	C ₂₁ H ₂₆ ClNO ₅	408

6.25. In Vitro Human SGLT2 Inhibition Assay

Human sodium/glucose co-transporter type 2 (SGLT2; accession number P31639; GI:400337) was cloned into pIRESpuro2 vector for mammalian expression (construct: HA-SGLT2-pIRESpuro2).

- 5 HEK293 cells were transfected with the human HA-SGLT2-pIRESpuro2 vector and the bulk stable cell line was selected in presence of 0.5 µg/ml of puromycin. Human HA-SGLT2 cells were maintained in DMEM media containing 10% FBS, 1% GPS and 0.5 µg/ml of puromycin.

- 10 The HEK293 cells expressing the human HA-SGLT2 were seeded in 384 well plates (30,000 cells/well) in DMEM media containing 10% FBS, 1% GPS and 0.5 µg/ml of puromycin, then incubated overnight at 37 C, 5% CO₂. Cells were then washed with uptake

buffer (140 mM NaCl, 2 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES, 5 mM Tris, 1 mg/ml bovine serum albumin (BSA), pH 7.3). Twenty microliters of uptake buffer with or without testing compounds were added to the cells. Then, 20 microliters of uptake buffer containing ¹⁴C-AMG (100 nCi) were added to the cells. The cell plates were incubated at 37°C, 5% CO₂ for 1-2 hours. After washing the cells with uptake buffer, scintillation fluid was added (40 microliters/well) and ¹⁴C-AMG uptake was measured by counting radioactivity using a scintillation coulter (TopCoulter NXT; Packard Instruments).

6.26. In Vitro Human SGLT1 Inhibition Assay

Human sodium/glucose co-transporter type 1 (SGLT1; accession number NP_000334; GI: 4507031) was cloned into pIRESpuro2 vector for mammalian expression (construct: HA-SGLT1-pIRESpuro2).

HEK293 cells were transfected with the human HA-SGLT1-pIRESpuro2 vector and the bulk stable cell line was selected in presence of 0.5 µg/ml of puromycin. Human HA-SGLT1 cells were maintained in DMEM media containing 10% FBS, 1% GPS and 0.5 µg/ml of puromycin.

The HEK293 cells expressing the human HA-SGLT1 were seeded in 384 well plates (30,000 cells/well) in DMEM media containing 10% FBS, 1% GPS and 0.5 µg/ml of puromycin, then incubated overnight at 37 C, 5% CO₂. Cells were then washed with uptake buffer (140 mM NaCl, 2 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES, 5 mM Tris, 1 mg/ml bovine serum albumin (BSA), pH 7.3). Twenty microliters of uptake buffer with or without testing compounds were added to the cells. Then, 20 microliters of uptake buffer containing ¹⁴C-AMG (100 nCi) were also added to cells. The cell plates were incubated at 37°C, 5% CO₂ for 1-2 hours. After washing the cells with uptake buffer, scintillation fluid was added (40 microliters/well) and ¹⁴C-AMG uptake was measured by counting radioactivity using a scintillation coulter (TopCoulter NXT; Packard Instruments).

6.27. Calculating IC₅₀ Values

The IC₅₀ of a compound with regard to a given target is determined by fitting the relevant data, using the Levenburg Marquardt algorithm, to the equation:

$$y = A + ((B-A)/(1+((C/x)^D)))$$

wherein A is the minimum y value; B is the maximum y value; C is the IC₅₀; and D is the slope. The calculation of the IC₅₀ is performed using XLFit4 software (ID Business

Solutions Inc., Bridgewater, NJ 08807) for Microsoft Excel (the above equation is model 205 of that software).

6.28. *In Vivo* Effect of Compounds

5 The pharmacological effects of compounds of the invention was determined using six drug-treated and six vehicle-treated c57 albino male mice weaned on 45% high fat diet and individually-housed in a Nalgene metabolic cage. The mice were provided drinking water and high-fat diet paste (2 parts diet to 1 part water) ad libitum.

10 Compounds were delivered two ways. In the first, mice were gavaged with drug or vehicle on day 1 with 5 ml/kg dose volume. The entire urine volume was collected for the following 24 hours into the metabolic cage plastic urine collector. Measures of mouse body weight, water consumption, food consumption (accounting for evaporation of water in the paste), and urine volume were made daily. Urine was collected daily, centrifuged, and assessed for glucose concentration using a Cobas Autoanalyzer. The final result of milligrams of glucose excreted per day was calculated from total urine volume and urine
15 glucose concentration.

In the second method, compounds were delivered in the diet. This was done by mixing the test compound in the high fat diet paste at the appropriate concentration, when taking into account baseline body weight and baseline food consumption. Paste containing the drug was again provided in excess each day. The amount of compound delivered per day
20 was confirmed by calculating animal body weight and food consumption.


Figure 1 shows the effect of four compounds of the invention (A, B, C and D), when orally dosed once at 30 mg/kg, on the amount of excreted glucose during the 24 hours following dosing. By comparison, control animals excreted about 1 mg glucose over the 24
25 hours.

All publications (*e.g.*, patents and patent applications) cited above are incorporated herein by reference in their entireties.

CLAIMS

What is claimed is:

1. A compound of the formula:



- 5 or a pharmaceutically acceptable salt or solvate thereof, wherein:

A is optionally substituted aryl, cycloalkyl, or heterocycle;

X is O, S or NR₃;

when X is O, R₁ is OR_{1A}, SR_{1A}, SOR_{1A}, SO₂R_{1A} or N(R_{1A})₂;

when X is S, R₁ is hydrogen, OR_{1A}, SR_{1A}, SOR_{1A}, or SO₂R_{1A};

- 10 when X is NR₃, R₁ is OR_{1A}, SR_{1A}, SOR_{1A}, SO₂R_{1A}, or R_{1A};

each R_{1A} is independently hydrogen or optionally substituted alkyl, aryl or heterocycle;

R₂ is fluoro or OR_{2A};

each of R_{2A}, R_{2B}, and R_{2C} is independently hydrogen, optionally substituted alkyl,


- 15 C(O)alkyl, C(O)aryl or aryl;

R₃ is hydrogen, C(O)R_{3A}, CO₂R_{3A}, CON(R_{3B})₂, or optionally substituted alkyl, aryl or heterocycle;


each R_{3A} is independently optionally substituted alkyl or aryl; and

each R_{3B} is independently hydrogen or optionally substituted alkyl or aryl.


- 20 2. The compound of claim 1, which is of the formula:



3. The compound of claim 2, which is of the formula:




4. The compound of claim 3, which is of the formula:



5. The compound of claim 1, wherein A is optionally substituted 6-membered aryl or heterocycle.
6. The compound of claim 1, wherein A is optionally substituted 5-membered heterocycle.
7. The compound of claim 1, wherein A is an optionally substituted fused bicyclic heterocycle.
8. The compound of claim 1, wherein X is O.
9. The compound of claim 1, wherein X is S.
10. The compound of claim 1, wherein X is NR₃.
11. The compound of claim 1, wherein R₁ is OR_{1A}.
12. The compound of claim 11, wherein R_{1A} is hydrogen.
13. The compound of claim 11, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
14. The compound of claim 1, wherein R₁ is SR_{1A}.
15. The compound of claim 14, wherein R_{1A} is hydrogen.
16. The compound of claim 14, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).

17. The compound of claim 1, wherein R_1 is SOR_{1A} .
18. The compound of claim 17, wherein R_{1A} is hydrogen.
19. The compound of claim 17, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
- 5 20. The compound of claim 1, wherein R_1 is SO_2R_{1A} .
21. The compound of claim 20, wherein R_{1A} is hydrogen.
22. The compound of claim 20, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
23. The compound of claim 1, wherein R_1 is $N(R_{1A})_2$.
- 10 24. The compound of claim 23, wherein at least one R_{1A} is hydrogen.
25. The compound of claim 23, wherein at least one R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
26. The compound of claim 1, wherein R_1 is hydrogen.
27. The compound of claim 1, wherein R_1 is R_{1A} .
- 15 28. The compound of claim 27, wherein R_{1A} is hydrogen.
29. The compound of claim 27, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
30. The compound of claim 1, wherein R_2 is fluoro.
31. The compound of claim 1, wherein R_2 is OR_{2A} .
- 20 32. The compound of claim 31, wherein R_{2A} is hydrogen.
33. The compound of claim 1, wherein R_{2B} is hydrogen.
34. The compound of claim 1, wherein R_{2C} is hydrogen.
35. The compound of claim 1, wherein R_3 is hydrogen.
36. The compound of claim 1, wherein R_3 is optionally substituted lower alkyl
- 25 (*e.g.*, optionally substituted methyl).

37. A compound of the formula:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

A is optionally substituted aryl, cycloalkyl, or heterocycle;

5 B is optionally substituted aryl, cycloalkyl, or heterocycle;

X is O, S or NR₃;

Y is O, S, SO, SO₂, NR₄, (C(R₅)₂)_p, (C(R₅)₂)_q-C(O)-(C(R₅)₂)_q, (C(R₅)₂)_q-C(O)O-(C(R₅)₂)_q, (C(R₅)₂)_q-OC(O)-(C(R₅)₂)_q, (C(R₅)₂)_q-C(O)NR₄-(C(R₅)₂)_q, (C(R₅)₂)_q-NR₄C(O)-(C(R₅)₂)_q, or (C(R₅)₂)_q-NR₄C(O)NR₄-(C(R₅)₂)_q;

10 when X is O, R₁ is OR_{1A}, SR_{1A}, SOR_{1A}, SO₂R_{1A} or N(R_{1A})₂;

when X is S, R₁ is hydrogen, OR_{1A}, SR_{1A}, SOR_{1A}, or SO₂R_{1A};

when X is NR₃, R₁ is OR_{1A}, SR_{1A}, SOR_{1A}, SO₂R_{1A}, or R_{1A};

each R_{1A} is independently hydrogen or optionally substituted alkyl, aryl or heterocycle;

15 R₂ is fluoro or OR_{2A};

each of R_{2A}, R_{2B}, and R_{2C} is independently hydrogen, optionally substituted alkyl, C(O)alkyl, C(O)aryl, or aryl;

R₃ is hydrogen, C(O)R_{3A}, CO₂R_{3A}, CON(R_{3B})₂, or optionally substituted alkyl, aryl or heterocycle;

20 each R_{3A} is independently optionally substituted alkyl or aryl;

each R_{3B} is independently hydrogen or optionally substituted alkyl or aryl;

each R₄ is independently hydrogen or optionally substituted alkyl;


each R₅ is independently hydrogen, hydroxyl, halogen, amino, cyano, OR_{5A}, SR_{5A}, or optionally substituted alkyl;

25 each R_{5A} is independently optionally substituted alkyl;


p is 0-3; and

each q is independently 0-2.


38. The compound of claim 37, which is of the formula:



39. The compound of claim 38, which is of the formula:



- 5 40. The compound of claim 39, which is of the formula:



41. The compound of claim 40, wherein A is optionally substituted 6-membered aryl or heterocycle.

- 10 42. The compound of claim 40, wherein A is optionally substituted 5-membered heterocycle.

43. The compound of claim 40, wherein A is an optionally substituted fused bicyclic heterocycle.

44. The compound of claim 40, wherein B is optionally substituted 6-membered aryl or heterocycle.

- 15 45. The compound of claim 40, wherein B is optionally substituted 5-membered heterocycle.


46. The compound of claim 40, wherein B is an optionally substituted fused bicyclic heterocycle.

47. The compound of claim 40, wherein X is O.

- 20 48. The compound of claim 40, wherein X is S.

49. The compound of claim 40, wherein X is NR_3 .
50. The compound of claim 40, wherein Y is $(\text{C}(\text{R}_4)_2)_p$.
51. The compound of claim 50, wherein p is 1.
52. The compound of claim 40, wherein Y is $(\text{C}(\text{R}_5)_2)_q\text{-C}(\text{O})\text{-(C}(\text{R}_5)_2)_q$.
- 5 53. The compound of claim 52, wherein each q is independently 0 or 1.
54. The compound of claim 40, wherein R_1 is OR_{1A} .
55. The compound of claim 54, wherein R_{1A} is hydrogen.
56. The compound of claim 54, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
- 10 57. The compound of claim 40, wherein R_1 is SR_{1A} .
58. The compound of claim 57, wherein R_{1A} is hydrogen.
59. The compound of claim 57, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
60. The compound of claim 40, wherein R_1 is SOR_{1A} .
- 15 61. The compound of claim 60, wherein R_{1A} is hydrogen.
62. The compound of claim 60, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
63. The compound of claim 40, wherein R_1 is SO_2R_{1A} .
64. The compound of claim 63, wherein R_{1A} is hydrogen.
- 20 65. The compound of claim 63, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
66. The compound of claim 40, wherein R_1 is $\text{N}(\text{R}_{1A})_2$.
67. The compound of claim 66, wherein at least one R_{1A} is hydrogen.
68. The compound of claim 66, wherein at least one R_{1A} is optionally substituted
- 25 alkyl (*e.g.*, optionally substituted lower alkyl).
69. The compound of claim 40, wherein R_1 is hydrogen.
70. The compound of claim 40, wherein R_1 is R_{1A} .

71. The compound of claim 70, wherein R_{1A} is hydrogen.
72. The compound of claim 70, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
73. The compound of claim 40, wherein R_2 is fluoro.
- 5 74. The compound of claim 40, wherein R_2 is OR_{2A} .
75. The compound of claim 74, wherein R_{2A} is hydrogen.
76. The compound of claim 40, wherein R_{2B} is hydrogen.
77. The compound of claim 40, wherein R_{2C} is hydrogen.
78. The compound of claim 40, wherein R_3 is hydrogen.
- 10 79. The compound of claim 40, wherein R_3 is optionally substituted lower alkyl (*e.g.*, optionally substituted methyl).
80. The compound of claim 40, wherein R_4 is hydrogen or optionally substituted lower alkyl.
81. The compound of claim 40, wherein each R_5 is hydrogen or optionally substituted lower alkyl (*e.g.*, methyl, ethyl, CF_3).
- 15 82. The compound of claim 39, which is of the formula:




wherein:

- each R_6 is independently hydrogen, hydroxyl, halogen, amino, cyano, nitro, $C\equiv CR_{6A}$, OR_{6A} , SR_{6A} , SOR_{6A} , SO_2R_{6A} , $C(O)R_{6A}$, CO_2R_{6A} , CO_2H , $CON(R_{6A})(R_{6A})$, $CONH(R_{6A})$, $CONH_2$, $NHC(O)R_{6A}$, $NHSO_2R_{6A}$, or optionally substituted alkyl, aryl or heterocycle;
- 20 each R_{6A} is independently optionally substituted alkyl, aryl or heterocycle;
- each R_7 is independently hydrogen, hydroxyl, halogen, amino, cyano, nitro, $C\equiv CR_{7A}$, OR_{7A} , SR_{7A} , SOR_{7A} , SO_2R_{7A} , $C(O)R_{7A}$, CO_2R_{7A} , CO_2H , $CON(R_{7A})(R_{7A})$, $CONH(R_{7A})$, $CONH_2$, $NHC(O)R_{7A}$, $NHSO_2R_{7A}$, or optionally substituted alkyl, aryl or heterocycle;
- 25 each R_{7A} is independently optionally substituted alkyl, aryl or heterocycle;


m is 1-3; and

n is 1-3.

83. The compound of claim 82, which is of the formula:



5 84. The compound of claim 83, which is of the formula:



85. The compound of claim 84, wherein X is O.

86. The compound of claim 84, wherein X is S.

87. The compound of claim 84, wherein X is NR₃.

10 88. The compound of claim 84, wherein R₁ is OR_{1A}.

89. The compound of claim 84, wherein R_{1A} is hydrogen.

90. The compound of claim 84, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).

91. The compound of claim 84, wherein R₁ is SR_{1A}.

15 92. The compound of claim 91, wherein R_{1A} is hydrogen.

93. The compound of claim 91, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).

94. The compound of claim 84, wherein R₁ is SOR_{1A}.

95. The compound of claim 94, wherein R_{1A} is hydrogen.

20 96. The compound of claim 94, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).


97. The compound of claim 84, wherein R_1 is SO_2R_{1A} .
98. The compound of claim 97, wherein R_{1A} is hydrogen.
99. The compound of claim 97, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
- 5 100. The compound of claim 84, wherein at least one R_1 is $N(R_{1A})_2$.
101. The compound of claim 100, wherein at least one R_{1A} is hydrogen.
102. The compound of claim 100, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
103. The compound of claim 84, wherein R_1 is hydrogen.
- 10 104. The compound of claim 84, wherein R_1 is R_{1A} .
105. The compound of claim 104, wherein R_{1A} is hydrogen.
106. The compound of claim 104, wherein R_{1A} is optionally substituted alkyl (*e.g.*, optionally substituted lower alkyl).
107. The compound of claim 84, wherein R_6 is hydrogen, hydroxyl, halogen, OR_{6A} or optionally substituted lower alkyl (*e.g.*, optionally halogenated methyl, ethyl, or isopropyl).
- 15 108. The compound of claim 107, wherein R_6 is hydrogen.
109. The compound of claim 107, wherein R_6 is halogen (*e.g.*, chloro).
110. The compound of claim 107, wherein R_6 is hydroxyl.
- 20 111. The compound of claim 107, wherein R_6 is OR_{6A} (*e.g.*, methoxy, ethoxy).
112. The compound of claim 107, wherein R_6 is optionally substituted methyl (*e.g.*, CF_3).
113. The compound of claim 84, wherein R_7 is hydrogen, $C\equiv CR_{7A}$, OR_{7A} or optionally substituted lower alkyl (*e.g.*, optionally halogenated methyl, ethyl, or isopropyl).
- 25 114. The compound of claim 113, wherein R_7 is hydrogen.
115. The compound of claim 113, wherein R_7 is $C\equiv CR_{7A}$.

116. The compound of claim 115, wherein R_{7A} is optionally substituted (e.g., with lower alkyl or halogen) monocyclic aryl or heterocycle.


117. The compound of claim 113, wherein R_7 is OR_{7A} (e.g., methoxy, ethoxy).

118. The compound of claim 113, wherein R_7 is acetylenyl or optionally substituted
5 methyl or ethyl.


119. The compound of claim 84, which is of the formula:




120. The compound of claim 84, which is of the formula:



10 121. The compound of claim 84, which is of the formula:




122. The compound of claim 84, which is of the formula:




123. The compound of one of claims 119-122, wherein X is O.

15 124. The compound of one of claims 119-122, wherein X is S.

125. The compound of one of claims 119-122, wherein X is NR₃.
126. The compound of claim 84, which is of the formula:




127. The compound of claim 84, which is of the formula:



5

128. The compound of one of claims 119-122, 126 or 127, wherein R_{1A} is hydrogen or optionally substituted methyl or ethyl.
129. A compound of the formula:



II

10

or a pharmaceutically acceptable salt or solvate thereof, wherein:

A is optionally substituted aryl, cycloalkyl, or heterocycle;

X is O or NR₃;

R₂ is fluoro or OR_{2A};

- 15 each of R_{2A}, R_{2B}, and R_{2C} is independently hydrogen, optionally substituted alkyl, C(O)alkyl, C(O)aryl or aryl;

R₃ is hydrogen or optionally substituted alkyl, aryl or heterocycle;

R₈ is hydrogen or C(O)R_{8A};

R_{8A} is hydrogen or optionally substituted alkyl, alkoxy or aryl;

R_{9A} and R_{9B} are each independently OR_{9C} or SR_{9C} , or are taken together to provide O, S or NR_{9C} ; and

each R_{9C} is independently optionally substituted alkyl, aryl or heterocycle.

130. The compound of claim 129, wherein A is optionally substituted 6-membered
5 aryl or heterocycle.

131. The compound of claim 129, wherein A is optionally substituted 5-membered heterocycle.

132. The compound of claim 129, wherein A is an optionally substituted fused bicyclic heterocycle.

10 133. The compound of claim 129, wherein R_2 is fluoro.

134. The compound of claim 129, wherein R_2 is OR_{2A} .

135. The compound of claim 134, wherein R_{2A} is hydrogen.

136. The compound of claim 129, wherein R_{2B} is hydrogen.

137. The compound of claim 129, wherein R_{2C} is hydrogen.

15 138. The compound of claim 129, wherein R_3 is hydrogen.

139. The compound of claim 129, wherein R_3 is optionally substituted lower alkyl (*e.g.*, optionally substituted methyl).

140. The compound of claim 129, wherein R_8 is hydrogen.

141. The compound of claim 129, wherein R_8 is $C(O)R_{8A}$.

20 142. The compound of claim 141, wherein R_{8A} is hydrogen.

143. The compound of claim 141, wherein R_{8A} is alkyl or alkoxy.

144. The compound of claim 129, wherein R_{9A} and R_{9B} are taken together to provide O, S or NR_{9C} .

145. The compound of claim 144, wherein R_{9C} optionally substituted alkyl.

25 146. A pharmaceutical formulation comprising a compound of one of claims 1, 33 or 129 and a pharmaceutically acceptable diluent or excipient.

147. A method of inhibiting SGLT2 activity, which comprises contacting SGLT2 with an effective amount of a compound of one of claims 1, 33 or 129.

148. A method of decreasing blood glucose in a patient, which comprises administering to the patient an effective amount of one of claims 1, 33 or 129.

149. A method of increasing the excretion of glucose in the urine of a patient, which comprises administering to the patient an effective amount of a compound of one of
5 claims 1, 33 or 129.

150. A method of restoring insulin sensitivity in a patient, which comprises administering to a patient in need thereof an effective amount of a compound of one of claims 1, 33 or 129.

151. A method of treating, managing or preventing a disease or disorder in a
10 patient, which comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of one of claims 1, 33 or 129, wherein the disease or disorder is atherosclerosis, cardiovascular disease, diabetes (Type 1 or 2), hyperglycemia, hypertension, a lipid disorder, obesity, or Syndrome X.

152. The method of claim 151, wherein the disease or disorder is type 2 diabetes.




FIG. 1

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2008/055775.

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D211/46 C07D309/10 C07D335/02 C07D407/12 A61K31/35
A61K31/38 A61K31/435 A61P3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HANDLON: "Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents" EXPERT OPIN. THER. PATENTS, vol. 15, no. 11, 2005, pages 1531-1540, XP002465936 cited in the application the whole document	1-128, 146-152
A	DE 10 2004 039096 A1 (BOEHRINGER INGELHEIM PHARMA [DE]) 23 February 2006 (2006-02-23) the whole document	1-128, 146-152
A	US 2006/189548 A1 (HIMMELSBACH FRANK [DE] ET AL) 24 August 2006 (2006-08-24) cited in the application the whole document	1-128, 146-152

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

27 May 2008

Date of mailing of the international search report

14/08/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fritz, Martin

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2008/055775

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-128; 146-152 (part)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-128;146-152(part)

Compounds I, sub-groups and pharmaceutical compositions thereof; methods of treatment involving the use of these compounds

2. claims: 129-145;146-152(part)

Compounds II, sub-groups and pharmaceutical compositions thereof; methods of treatment involving the use of these compounds

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2008/055775

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 102004039096 A1	23-02-2006	NONE	
US 2006189548 A1	24-08-2006	AR 056185 A1	26-09-2007
		CA 2595257 A1	31-08-2006
		WO 2006089872 A1	31-08-2006